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CLINICAL FEATURES AND EVALUATION OF RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by symmetrical 
inflammation of multiple joints. The prevalence of RA in the Western population is estimated 
to be 1% and is three times more frequent in females than in males.  
The burden of disease is high and patients typically present with pain, symmetrical swelling of 
small joints, morning stiffness and a general feeling of despair and fatigue.  
In the long term, the cartilage and bone of the affected joints are damaged. This development 
of erosive disease is generally regarded as irreversible and greatly impairs the function of the 
joints, leading to a loss of quality of life for the patient. 
RA is a progressive disease, with periods of remission and periods of exacerbation. 
Permanent remission occurs, but is rare once joint damage has started. Without treatment, 
RA not only leads to severe joint deformations and loss of function, but ultimately to 
premature death due to cardio vascular disease, infections, renal disease, respiratory disease 
and RA itself1,2.  
 
To reliably evaluate disease activity, numerous composite measures have been developed. 
The most frequently used combined measure of disease activity in Europe and this thesis is 
the disease activity score (DAS28). This composite measure includes a count of the number 
of swollen and painful joints out of a selection of 28 joints in shoulders, elbows, wrists, 
metacarpophalangeal joints, proximal interphalangeal joints and the knees; a measure of 
global health from the patients’ perspective on a 100 mm visual analogue scale; and a 
measure of the acute phase response (the erythrocyte sedimentation rate or C-reactive 
protein3,4. The long term damage to the joints can be visualized by radiographs and quantified 
by several scoring techniques5-8. The total damage score combines the severity of damage to 
individual joints in hands and feet and is regarded as an important long term outcome 
measure in RA. The patients’ physical disability is often assessed by the health assessment 
questionnaire (HAQ) on which patients can fill out their impairments, resulting in a total 
disability score9,10.  
 
In recent decades the prognosis for patients with RA has improved considerably due to 
greatly expanded treatment options.  
 
TREATMENT HISTORY 
Despite discovery of salicylates in the 19th century, therapy of RA was mostly non-
pharmacological and of very limited efficacy. Salicylates have analgesic and anti-inflammatory 
properties similar to what we now call non-steroidal anti inflammatory drugs (NSAIDs) such as 
ibuprofen and diclofenac, but with a less favorable safety profile11. In the early 20th century, 
Jacques Forestier was the first to discover the effectiveness of gold compounds for the 
treatment of RA12,13, which was the start of the discovery of the so called disease modifying 
anti rheumatic drugs (DMARDs). Although the exact mode of action of these drugs is not yet 
understood, research shows they can suppress the primary inflammation process and delay 
radiographic progression14-16. While the first experiments with the DMARDs sulfasalazine 
(SSZ) and hydroxychloroquine were performed17-19, Hench and his co-workers found that 
glucocorticoids (GCs) dramatically improved the symptoms of patients with RA, which was 
rewarded with the Nobel prize in 195020,21. These spectacular results led to the widespread 
use of high doses of GCs, but changed drastically when the spectrum of unacceptable side 
effects was disclosed. This shifted the focus of research once again towards development 
and experiments with NSAIDs and DMARDs, leading to the introduction of indomethacine, 
followed by many other NSAIDs, and also the currently most often used drug methotrexate 
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(MTX)22,23. Despite fear of side effects, many rheumatologists continued to use GCs and due 
to trials demonstrating their high effectiveness and disease modifying properties24-28 there is 
renewed interest in their use. Current debate is focused on adequately balancing the benefits 
and risks of GC therapy and performing the studies necessary to fill the knowledge gap 29-31. 
 
The order in which drugs were discovered and introduced for the treatment of RA reflects the 
traditional treatment approach of RA, called the pyramid approach: treatment started with an 
NSAID; if this proved insufficient, a single DMARD was started32,33. The slow onset of action 
of most DMARDs meant a minimum of 3 months was needed to show effect. Consequently, 
once a single DMARD was able to suppress the disease effectively, damage to joints had 
already started. In fact, many rheumatologists waited for such evidence before starting 
second-line therapy. The first to challenge the pyramid approach were Wilske and Healey in 
1989 who argued that the pyramid should be inverted following a step-down approach with 
aggressive treatment in the earliest state of the disease34. This change in paradigm led to 
clinical trials demonstrating experimental treatments with combinations of different DMARDs. 
The COBRA trial published in 1997 was one of the first trials validating the reverse pyramid 
strategy by demonstrating the effectiveness of a combination of different DMARDs with a high 
oral pulse of prednisolone, and is the foundation of this thesis35. 
 
THE COBRA TRIAL 
In the COBRA trial, 155 patients with early and active RA were randomized to receive either 
sulfasalazine monotherapy or COBRA combination therapy. COBRA therapy comprises 
sulfasalazine, methotrexate and high initial dose prednisolone. Prednisolone is rapidly tapered 
in 7 weeks to 7.5 mg a day, and stopped after 28 weeks. Methotrexate is tapered and stopped 
after 40 weeks, while sulfasalazine is continued. This treatment regime resulted in earlier 
disease suppression and a delay in radiographic progression compared to SSZ mono 
therapy35. This benefit of delayed radiographic progression was still detectable after 5 years 
follow up18. The BeSt trial recently showed that COBRA therapy is as effective as initial 
combination therapy of high-dose MTX with infliximab25;36 and Verschueren and colleagues 
demonstrated the feasibility of COBRA therapy in daily practice37. It follows that COBRA 
therapy, a combination of inexpensive, generic drugs, is a highly cost-effective treatment of 
early RA38,39. 
Ten years after the start of the COBRA trial, researchers wondered why COBRA therapy was 
not used regularly in clinical practice. Chapters 1.1 and 1.2 of this thesis provide answers to 
this question40,41. Another research question focused on the long term safety of COBRA 
therapy. To investigate the long term consequences of COBRA therapy, we performed a 
follow up study of the original COBRA trial. Chapter 1.3 presents the survival, comorbidities, 
radiological progression and general health situation of the patients 11 years after the COBRA 
trial. Chapter 1.4 explores the possibilities of predicting long term radiological damage by 
baseline measurements of bone and cartilage markers. Chapter 1.5 closes the first section of 
this thesis with the presentation and pilot test of our COBRA implementation plan. 
 
MODERN TREATMENT 
Since the pyramid approach, treatment of RA has changed drastically; four important 
elements of modern RA treatment can be identified: early intervention, combination therapy, 
biologicals and monitoring strategies.  
Because radiological progression starts early in the course of disease, it is important that 
diagnosis and treatment of patients takes place as early as possible. Research has shown 
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that early intervention in the course of the disease, suppressing inflammation as quickly as 
possible, can delay or even prevent joint destruction42-47.  
To rapidly suppress inflammation, research shows that a strong, aggressive therapy with a 
combination of DMARDs is more effective than monotherapy. Well known combination 
therapies are the O’Dell combination which combines sulfasalazine, methotrexate and  
hydroxychloroquine48; the FINRACo combination  including sulfasalazine, methotrexate, 
hydroxychloroquine, and prednisolone48; and of course the COBRA combination35. 
 
An important development in the field of modern RA treatment is the discovery of biological 
therapies. Biologicals are drugs made through biotechnology, targeted against specific 
mediators in the inflammatory cascade. They have shown to be most effective in combination 
with a DMARD (often MTX), rather than as monotherapy50-53. The focus of this thesis is more 
on the use of conventional combination therapy for the treatment of early RA, but chapters 
2.1 and 2.2 present a pilot study in which the TNF-α-antagonist infliximab acts as an 
intensification drug during remittive therapy, resulting in a unique response54.  
The three elements of modern RA treatment described above are all combined in the final 
element: intensive monitoring. While standard care implies the start of an effective treatment 
with regular checks of side effects, a tight monitoring approach allows the clinician to rapidly 
adjust therapy based on regular measurements (monitoring) of disease activity. Several 
recent studies have shown that through monitoring of disease activity and rapid adjustment of 
treatment, more patients can achieve a state of remission36;49;55,56. The BeSt study compared 
four different treatment strategies all monitored by the DAS; all four treatments were highly 
effective in combination with tight monitoring, but the initial combination strategies were 
superior due to earlier suppression of inflammation and subsequently less progression of joint 
damage36. The TICORA trial is another good example of the benefit of monitoring on disease 
activity. In this trial, 65% of the patients in the monitoring arm achieved DAS remission, 
compared to 16% in the usual care arm, with a 6 times higher odds for the intensive 
monitoring group to achieve a good EULAR response compared to the routine care group55. 
Still, the earliest and most effective trial that studied a novel combination therapy combined 
with a monitoring strategy was the FIN-RACo trial, in which 68% of the patients achieved 
DAS28 remission57. Chapter 2.1 of this thesis presents our own tight control pilot study in 
which we test the feasibility of a new monitoring strategy based on measurements of a 
biochemical marker of cartilage degradation called urinary excretion of C-terminal cross 
linking of type-II collagen (CTX-II)54.  
 
GOAL OF TREATMENT 
Remission is the ultimate goal of RA treatment, but the definition and measurement of this 
state is not straightforward. The most simple definition one easily thinks of is ‘the absence of 
disease’, but the past years of developing remission criteria that were truthful as well as 
discriminative but still feasible did not provide trialists or practitioners with a uniform measure 
of remission. In fact, the multitude of definitions for remission used in rheumatology clinical 
trials lead to different results with regard to remission rates and make reported remission 
rates in clinical trials difficult to interpret58-61. Given these concerns, the American college of 
Rheumatology (ACR), the European League Against Rheumatism (EULAR) and the Outcome 
Measures in Rheumatology initiative (OMERACT) constituted an international committee of 
rheumatoid arthritis clinical researchers, trialists and clinical epidemiologists to redefine 
remission in RA. Their charge was to study current definitions of remission, explore the 
theoretical underpinning of the concept of remission, and develop a research agenda that 
would inform future work in the development of a new definition. Chapters 3.1 and 3.2 
present their work in progress. 
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OUTLINE OF THIS THESIS 
This thesis comprises three sections.  
Section I contains five chapters on the implementation of COBRA therapy in clinical practice. 
Chapter 1.1 presents the results of a short questionnaire among Dutch rheumatologists 
giving a first indication of their reluctance to use this therapy. Chapter 1.2 presents an in-
depth qualitative analysis of both rheumatologists’ and patients’ feelings towards the use of 
COBRA therapy, and provides clues on how to approach implementation. To evaluate long 
term safety of COBRA therapy, chapter 1.3 presents the survival, comorbidity, radiographic 
progression and general health of the original COBRA cohort 11 years after the trial. Chapter 
1.4 evaluates possibilities of predicting long term radiological damage by studying bone 
markers measured before and during the original COBRA trial. Chapter 1.5 presents the 
design and pilot test of an implementation plan to facilitate the use of COBRA therapy in 
clinical practice.  
Section II presents the COBRA-CTX study, a pilot trial in which we combine a novel DMARD 
combination treatment, with intensification of treatment based on the achievement of either 
clinical remission or ‘bone marker’ remission. Chapter 2.1 presents the complete pilot trial 
and chapter 2.2 highlights the sharp decrease of important biomarkers of rheumatoid arthritis, 
rheumatoid factor and anti-cyclic citrullinated peptide, during this treatment. 
Section III presents the ongoing work of the ACR/EULAR/OMERACT remission committee 
on the development of a new definition of remission in rheumatoid arthritis with chapter 3.1 
describing the research agenda developed during the first committee meeting. Where most 
theses start, this thesis ends with a review of the literature in chapter 3.2: studying the 
longitudinal association between remission and long term RA outcome, to support the 
ACR/EULAR/OMERACT committee in the development of a new definition of remission. 
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ABSTRACT 
 
 
OBJECTIVE 
The COBRA trial has proved that combination therapy with prednisolone, methotrexate and 
sulfasalazine is superior to sulfasalazine monotherapy in suppressing disease activity and 
radiological progression of early rheumatoid arthritis (RA). In addition, five years follow up 
proved that COBRA therapy results in sustained reduction of the rate of radiologic 
progression. Despite this evidence Dutch rheumatologists appear reluctant to prescribe 
COBRA therapy. 
This study was carried out to explore the reasons for the Dutch reluctance to prescribe 
COBRA therapy. 
 
METHODS 
A short structured questionnaire based on social-psychological theories of behaviour was sent 
to all Dutch rheumatologists (N=230). 
 
RESULTS 
The response-rate was 50%. COBRA therapy was perceived as both effective and safe, but 
complex to administer. Furthermore, rheumatologists expressed their concern about the large 
number of pills that had to be taken, the side effects of high dose prednisolone, and the low 
dose of methotrexate. Although the average attitude towards the COBRA therapy was slightly 
positive (above the neutral point), the majority of responding rheumatologists had a negative 
intention (below the neutral point) to prescribe COBRA therapy in the near future.  
 
CONCLUSION 
The reluctance of Dutch rheumatologists towards prescribing the effective COBRA therapy 
may be due to the perceived complexity of the treatment schedule and the negative patient-
related consequences of the therapy. 
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INTRODUCTION 
In the randomised, double blind, multicenter COBRA trial, published in 1997, 155 patients with 
early rheumatoid arthritis (RA) were treated with either sulfasalazine (SSZ) monotherapy or 
COBRA combination therapy, comprising SSZ (2 g/day), methotrexate (MTX; 7.5 mg/week), 
and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 7.5 mg/day); see Figure 1. 
The COBRA combination was found to be superior to SSZ monotherapy in suppressing 
disease activity and radiological progression of early RA1. After 5-year follow up, the COBRA 
therapy resulted in sustained reduction of the rate of radiologic progression despite similar 
treatment and disease activity in the follow up period2 and was proven cost-effective due to 
enhanced efficacy at lower or equal direct costs compared to SSZ monotherapy3,4. 
In addition, the BeSt trial, comparing clinical and radiographic outcomes of four treatment 
strategies, showed equal effectiveness of the COBRA strategy to initial combination therapy 
with infliximab. This resulted in earlier functional improvement and less radiographic damage 
after one year, compared to sequential monotherapy or step-up combination therapy5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  COBRA treatment schedule 
 
 
Despite the evidence on short- and long term effectiveness and safety of the COBRA 
combination therapy and its cost-effectiveness, it appears that this therapy is seldom 
prescribed in clinical practice. 
This study was designed to explore the use of COBRA therapy in Dutch clinical practice and 
to explain the reservation of Dutch reumatologists towards its prescription. 
 
METHODS 
A short structured questionnaire was designed with questions partially based on the social 
psychological Theory of Planned Behaviour. This theory predicts behaviour (in our case, 
prescribing COBRA therapy) through behavioural intention, which in turn is explained through 
attitude towards the behaviour, the influence of the social environment and the self-perceived 
control over the behaviour6,7. The first question probed familiarity with COBRA therapy by 
asking respondents if they had heard of the COBRA therapy and whether or not they had ever 
used this therapy in their clinical practice or through trials.  
The attitude towards prescribing the COBRA therapy was measured through 7 word pairs 
(ineffective vs. effective; unsafe vs. safe; complex vs. simple; patient unfriendly vs. patient 
friendly; unsympathetic vs. sympathetic; unnecessary vs. necessary; bad vs. good) on a 7-
point ‘Likert scale’. Negatively worded items were recoded for analysis. Thus, a score of 1 
indicates a negative attitude towards prescription of COBRA therapy and a score of 7 
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indicates a positive attitude towards prescribing COBRA therapy. Overall attitude was 
calculated as the grand mean of all the individual items. 
Intention was measured through a single item querying the likelihood the respondent would 
prescribe COBRA therapy to a newly diagnosed RA patient within the next 6 months (1 “not at 
all likely” to 7 “very likely”). Questionnaires were sent by surface and electronic mail to all 
Dutch rheumatologists and rheumatologists in training, members of the Dutch Society of 
Rheumatology (N=230). 
 
Analyses 
Results were statistically analysed by parametrical (t) and nonparametrical (Mann-Whitney) 
tests where applicable and linear stepwise regression analysis was used to explore 
relationships between variables. Remarks written on the questionnaire were categorized by 1 
investigator and judged by 2 other investigators.  
 
RESULTS 
The response to the questionnaire was 50% (n=116). All respondents were familiar with 
COBRA therapy; two third had used it in clinical practice, the remainder had participated in a 
trial. Thirteen respondents were trainees. Overall, the attitude towards prescribing COBRA 
therapy was slightly positive (Table 1). The high score of 6 shows respondents were 
convinced of the effectiveness of COBRA therapy. All other items scored a slight plus, except 
for a slight minus on simplicity and a neutral on patient friendliness. All items except patient 
friendliness scored significantly different from the neutral point 4. In contrast to these findings, 
the mean score on intention to prescribe the COBRA therapy to early RA patients within the 
near future remained slightly negative. Distribution of items was reasonably normal, except for 
the items complexity with some skewness towards lower values (data not shown) and 
intention, which showed a bimodal distribution (Figure 2).  
 
 
Table 1   Dutch rheumatologists’ attitude towards prescribing COBRA therapy  
  Attitude  
 1 –– 2 –– 3 ––  4 –– 5 –– 6 –– 7 
Mean (SD)  
  Ineffective –  Effective 6.0  (0.7) *** 
  Unsafe –  Safe 4.8  (1.2) *** 
  Complex –  Simple 3.3  (1.4) *** 
  Patient unfriendly –  Patient friendly 3.9  (1.4) 
  Unsympathetic –  Sympathetic 4.3  (1.2) * 
  Unnecessary –  Necessary 4.5  (1.2) *** 
  Bad –  Good 4.9  (1.1) *** 
Overall  Negative –  Positive 4.5  (0.7) *** 
Intention to use  Not Likely At All –  Highly Likely 3.5  (2.0) ** 
Higher numbers indicate more positive ratings. Items scored significantly different from the neutral point of 4 with:  
*p<0.05; **p<0.01; ***p<0.001  
 
 
Respondents experienced with COBRA scored significantly higher on both attitude and 
intention compared to ‘unexperienced’ respondents: 4.7 v 4.3 and 4.7 v 4.1 (both: p<0.001). 
Stepwise regression analysis showed the variance in intention to prescribe COBRA was 
significantly explained by attitude towards prescribing COBRA therapy (R2change=0.15; 
p=0.002) and by prior experience with the COBRA therapy (R2change=0.15; p=0.001). There 
were no significant differences between trainees and rheumatologists, but the number of 
trainees responding was very small. 
Remarks written on the questionnaires could be divided into 6 categories, shown in Table 2. 
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Figure 2   How likely is it that you will prescribe COBRA therapy to a patient in the coming 6 months? 
 (1 “not at all likely” to 7 “very likely”) 
 
 
 
Table 2   Remarks of respondents written on the questionnaire 
 Remarks Frequency (n=34) 
1 Prefer the use of a mild/revised COBRA therapy  14 
2 All early RA patients are enrolled in protocols  5 
3 Prefer the use of steroid injections  5 
4 Prescribing COBRA is complicated for the doctor  4 
5 Using COBRA is unpleasant for the patient  
(referring to the amount of pills and side effects) 
 4 
6 Other remarks *  6 
* Problem with the combination SSZ-MTX / preference for other medications 
 
 
The most prevalent remark was the preference of respondents for using a “mild” or “revised” 
COBRA therapy. The suggestions and adjustments that respondents made to the therapy 
were the exclusion of SSZ from the medication strategy (n=5), the use of higher doses of 
MTX (n=5) or continuation of the therapy after 40 weeks with MTX instead of SSZ (n=4). 
Remarks about high dose prednisolone were mainly focused on the unpleasant side effects 
for patients, the suggestion that a lower dose might also suffice and the preference for 
injections instead of oral steroids. 
 
DISCUSSION 
This study explored the reluctance of Dutch rheumatologists to prescribe COBRA therapy. 
Although most scores (except effectiveness) were on average near the neutral point, it found 
a discrepancy between a positive attitude and a negative intention, with a strong cluster of 
respondents that do not want to prescribe COBRA therapy.  
Some clues to explain this come from the other items and especially the added remarks. The 
schedule is perceived as somewhat complex, and several rheumatologists appear to prefer 
their own mild/revised COBRA therapy in daily practice. In addition, respondents criticise the 
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inclusion of SSZ in the COBRA treatment schedule and the dosage of MTX, which at 7.5 mg 
weekly is low by current standards. Finally, several remarks are aimed at prednisolone: a 
preference for injections, and the perception that patients object to high dose prednisolone 
and a large amount of pills. The more positive attitude and intention of rheumatologists who 
had experience with the COBRA therapy (compared to ‘unexposed’ rheumatologists) 
suggests that encouraging such practical experience is a feasible way to increase 
implementation of COBRA therapy in daily practice.  
However, this study did not measure social norm and perceived behavioural control, important 
factors in explaining behaviour. Because of the finding that the COBRA therapy was 
perceived as slightly complex, rheumatologists might find it difficult to prescribe this therapy 
(perceived behavioural control). Furthermore, the perception of the behaviour of colleagues 
may also be important in whether or not to prescribe a therapy that not many others do (social 
influence).  
Another limitation of this study is the selection of rheumatologists. Though all Dutch 
rheumatologists and trainees were invited to respond, only 50% did. This could introduce bias 
in terms of the ‘population’ mean opinion of Dutch rheumatologists. However, more than 
enough material was obtained in this exploratory first step. The next step is in-depth 
exploration of physicians’ and patients’ opinions via focus groups and interviews (currently 
ongoing, to be reported separately). This information will be crucial in designing an 
implementation project addressing the problems that respondents have with prescribing the 
COBRA therapy in their daily practice. 
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ABSTRACT 
 
 
OBJECTIVE  
COBRA therapy has proven to be an effective treatment for early rheumatoid arthritis (RA), 
but is rarely prescribed. A survey showed reluctance of Dutch reumatologists to apply COBRA 
therapy in early RA. The present qualitative study was carried out to further explore the 
reservation of Dutch rheumatologists towards prescribing COBRA therapy and include 
patients’ view on (components of) COBRA therapy. 
 
METHODS 
Two focus group discussions were undertaken for rheumatologists (n1=8, n2=7) and two for 
patients (n1=4, n2=8). In addition, in depth interviews were conducted with 11 rheumatologists 
and one patient. These were taped and transcribed. Two independent researchers identified 
themes and these were discussed with three other researchers. 
 
RESULTS  
Rheumatologists were positive concerning effectiveness of COBRA therapy, but highly 
concerned about their patients’ possible negative reaction to the large amount of pills to be 
prescribed. In addition, rheumatologists perceived lack of time explaining and prescribing 
COBRA therapy and felt uncomfortable prescribing high doses of prednisolone. Patients were 
positive about an aggressive combination therapy such as COBRA, and they had no qualms 
taking many pills if this could improve their prognosis. Patients associated prednisolone with 
negative side-effects, but were also aware of the benefits and the need of prednisolone in 
rough times. A decrease in the amount of pills after intensive treatment was highly 
appreciated.  
 
CONCLUSION 
Rheumatologists and patients differed in opinion about the use of COBRA therapy. 
Rheumatologists were particularly concerned about their patients’ reaction towards them 
prescribing such an aggressive and complex therapy, whereas patients, while aware of the 
side-effects, were most interested in suppressing illness symptoms and reducing future 
damage regardless of the amount of pills. 
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INTRODUCTION 
In the last decade knowledge on the optimal treatment of rheumatoid arthritis (RA) has greatly 
increased. Nowadays, it is generally accepted that initial combination therapy and biologic 
agents are more effective than single disease modifying anti-rheumatic drug (DMARD)-
therapy1-5, although evidence is not conclusive yet6. As biologic agents are not commonly 
introduced at the onset of disease, combination therapy constitutes the obvious choice for 
treatment of early RA.  
The COBRA therapy (acronym meaning: COmBination therapy in early Rheumatoid Arthritis) 
is a step-down combination strategy comprising sulfasalazine (SSZ, 2 g/day), methotrexate 
(MTX, 7.5 mg/week), and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 7.5 
mg) (see Figure 1). COBRA therapy has been shown to be very effective in the treatment of 
early RA. The original trial reported in 1997 showed that treatment with COBRA therapy leads 
to faster suppression of disease activity and delay in the rate of radiological progression of 
early RA, compared to traditional monotherapy with sulfasalazine7. Disease activity was 
almost immediately improved in patients using the COBRA therapy, toxicity was low and costs 
of the treatment were equal to those of SSZ monotherapy8,9. Five year follow up by Landewé 
et al showed that damage control persists for up to 5 years after treatment, independent of 
subsequent DMARD use and disease activity10. 
More recently, the BeSt trial, comparing clinical and radiographic outcomes of four treatment 
strategies, showed equal effectiveness of COBRA therapy to initial combination therapy of 
high-dose MTX with infliximab. This resulted in earlier functional improvement and less 
radiographic damage after one year, compared to sequential monotherapy or step-up 
combination therapy11,12. 
Despite this irrefutable evidence for effectiveness of COBRA therapy, former research 
showed reluctance of Dutch reumatologists to apply COBRA therapy in early RA13. The 
average attitude towards the COBRA therapy was positive, and was mainly caused by high 
scores on the items effectiveness and safety. However, COBRA therapy was also perceived 
as somewhat complex to administer. In contrast to this positive attitude, most respondents did 
not intend to prescribe COBRA therapy in the near future. 
In order to better understand this discrepancy and to include patients’ view on COBRA 
therapy, we performed the present qualitative study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  COBRA combination therapy 
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METHODS  
To investigate the opinions and beliefs regarding all aspects of COBRA combination therapy, 
a qualitative approach was used, combining focus group discussions and semi-structured in-
depth telephone interviews. Focus group research is qualitative research that gathers rich, 
descriptive data from participants convened in small, homogeneous groups, focusing on a 
specific topic. The emphasis is on understanding participants’ experiences, attitudes, 
perspectives and assumptions through interaction between respondents14. The idea is that 
every finding is equally important regardless of the number of times mentioned. The nature of 
in-depth interviews is more structured than that of focus group discussions and focuses 
deeply on the opinion of the individual. 
 
Participants 
Rheumatologists (main focus of research) 
Opinions and beliefs of rheumatologists towards COBRA therapy were the main focus of our 
study. Firstly, a random selection of seventeen rheumatologists working in the two academic 
hospitals and the Jan van Breemen Institute in Amsterdam were invited to participate in a 
focus group discussion. This resulted in a group of 8 participants. Secondly, all 
rheumatologists that had participated in the original COBRA trial (n=10) were invited for a 
focus group discussion. These rheumatologists formed a group of 7 participants. 
Thirdly, the research team identified opinion leaders from the Dutch rheumatology field, based 
on their role as professor of rheumatology, an educator of new rheumatologists or a 
rheumatologist working in a large peripheral hospital. Due to their busy schedules, they were 
invited for an in-depth telephone interview.  Out of twenty invited opinion leaders, 11 
accepted. 
Patients 
Firstly, the rheumatologists of the research team invited eight patients with established RA 
from their own practice; one rheumatologist selected two patients exposed to COBRA 
therapy; one rheumatologist invited two patients currently on anti-TNF therapy and two 
rheumatologists both selected two patients exposed to prednisolone. This resulted in a group 
with 4 patients, one with COBRA experience, two with at least anti-TNF experience and one 
with at least prednisolone experience. 
Secondly, thirty-two patients that were active members of the national patient rheumatic 
association in the central region of the Netherlands were invited. These patients, listed as 
tutors and volunteers to help new patients with rheumatic diseases, formed a group of 8 
participants. In addition, one patient unable to take part in the group, was invited for an in-
depth telephone interview. 
Invited participants (rheumatologists and patients) that did not attend informed us that they 
were unable to meet at the appointed date. 
 
Data collection 
The structure of the focus group discussions and in-depth interviews is shown in Table 1. The 
study focused mainly on the rheumatologists as the prime target for implementation efforts. 
Thus for the rheumatologists data collection continued until saturation was reached. In 
contrast, we felt it was important to research patient opinion, but did not seek saturation. In all 
contacts with patients, a short scenario was presented in which they were asked to imagine 
that they came to the rheumatologist for the first time with their complaints and that the 
COBRA therapy was explained to them (see supplementary data).  Participants were 
reassured that their expressions during the focus groups and interviews would be 
anonymously reported.  Before the start, all participants gave their informed consent. All focus 
group discussions and in-depth interviews were conducted, taped and transcribed by the 
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same researcher (LvT), who was not involved as a rheumatologist or in the clinical care 
management of any of the patient participants. Under Dutch law, this research does not need 
approval from an Ethical Review Board. This study was conducted between May 2005 and 
June 2006. 
 
 
Table 1   Basic structure of the focus group discussions and interviews 
Rheumatologists 
How do you treat most of your early RA patients? 
Did you ever use COBRA combination therapy or a related combination therapy? 
What are the advantages of COBRA combination therapy in the treatment of early RA? 
What are the disadvantages of COBRA combination therapy in the treatment of early RA? 
How do you feel about sulfasalazine, methotrexate and prednisolone? 
How do you feel about the dosage in which these medications are used in the COBRA 
therapy? 
Do you think there is enough scientific evidence to support the COBRA therapy? 
What should be changed regarding the COBRA therapy, to make you prescribe it more 
often to early RA patients? 
Patients 
What is your experience regarding the treatment of your arthritis? 
With what treatment have you had a good experience, with what treatment a bad 
experience? 
How do you feel about sulfasalazine, methotrexate and prednisolone? What is your 
experience with these drugs? 
What aspects of treatment are important to you? 
Presentation of COBRA scenario (see supplementary data) 
Feedback on COBRA scenario 
RA: rheumatoid arthritis; COBRA: acronym meaning ‘COmBination therapy in early Rheumatoid Arthritis’ 
The nature of in-depth interviews is more structured then that of focus group discussions 
 
 
Data analyses 
During the focus group discussions and interviews, the responses of the participants were 
thoroughly investigated through the formulation of questions like: ‘Why do you do that?’ or ‘In 
what way do you mean this?’ The data was analysed according to the interpretative 
phenomenological analysis (IPA) method15,16, which not only shows the content of the 
qualitative data, but also searches for underlying cognitive and emotional concepts. The IPA 
method is a data driven, bottom-up approach that avoids prior assumptions to minimize bias. 
To further reduce the chance of bias, transcripts were cross validated through researcher 
triangulation: two independent researchers (LvT and AP) systematically searched for themes 
in the first group, forged connections between themes, then moved on to the next group. After 
all transcripts were analysed, the two independent researchers agreed to the same set of 
major themes. Further data exploration created new categories, which were grouped in the 
themes. Themes were discussed and agreed upon by three other researchers. All transcripts 
were analyzed using the same techniques with opinions and feelings towards components of 
the COBRA therapy being the main focus of the analytical procedure. Data analysis was 
carried out using NVivo software for coding. Because of the qualitative nature of the data, 
frequencies are stated in broad term (some, many, all), and no statistical tests were used. 
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RESULTS  
Twenty-six rheumatologists participated, with a mean number of 23 years of experience 
(median: 25; range: 1-34). Nineteen rheumatologists were male. Thirteen patients with 
rheumatic diseases (rheumatoid arthritis (n=11), psoriatic arthritis (n=1) and juvenile 
inflammatory arthritis (n=1)) participated. The mean duration of disease for patients was 22 
years (median: 21; range: 1-50). Three patients were male. 
The results of rheumatologists and patients are discussed separately and presented using 
summaries and quotes (rheumatologists are shortened to ‘R’ and patients are shortened to 
‘P’). 
 
Rheumatologists 
Most rheumatologists treated their early RA patients with MTX, starting with 7.5 or 10 mg 
during the first weeks, and increasing this to a maximum of 25 within 2 or 3 months. For 
patients with a very active disease, some added glucocorticoids, preferably by injection in the 
affected joint(s), otherwise prednisolone orally up to 15 mg as bridge therapy. The major 
determinants for a rheumatologist’s choice of medication were the patient’s disease activity 
and prognostic factors. In addition, comorbidity, personal desires of a patient, the duration and 
location of disease, and age of a patient were taken into account. On average, 
rheumatologists saw 2 to 3 newly diagnosed RA patients per month. Participants rarely 
prescribed COBRA therapy and were unfamiliar with its exact treatment schedule. Four main 
themes could be identified: patient-related concerns; personal perceived barriers (practical 
and emotional); societal implications and perceived value of scientific evidence. 
 
Patient-related concerns 
Rheumatologists emphasized the negative aspects of the COBRA therapy for the patient. 
Their main concern was the large number of tablets that has to be taken (the three drugs 
sulfasalazine, methotrexate and prednisolone, with additional folic acid and bisphosphonates) 
and the kind of tablets (large tablets of sulfasalazine).  
 
R-F : “I personally would find it extremely annoying to swallow such large pills.” 
 
They were worried about their patients’ opinion about themselves (the practicing physician) 
and they expected that their patients would strongly oppose against the use of prednisolone; 
in addition, rheumatologists felt uncomfortable with the possibility of a bloated ‘cushing face’. 
 
R-G : “The patient leaves the room and says: ‘this doctor is completely nuts. I enter 
with pain in my wrist and I leave with 8 different kinds of tablets!’ ” 
R-J : “Very often it depends on the patient. When you mention the word [red: 
prednisolone] it makes their hair stand on end.” 
 
On the other hand, rheumatologists also saw great advantages of aggressive combination 
therapy for the patient: 
 
R-T8 : “The first blow is half the battle, if you can simply convince the patient and 
improve their condition.” 
 
Personal perceived barriers 
In the discussion of positive and negative aspects of COBRA therapy, two types of personal 
perceived barriers were identified: practical or workload related barriers and emotional 
barriers. 
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Some rheumatologists felt that explaining COBRA therapy to a patient took so much effort 
and time: 
 
R-J : “It takes a lot of talking to convince a patient that this is very good for him.” 
R-C : “Way too much work, I only have 10 minutes...” 
Emotional statements were made about the COBRA therapy as a whole, but especially the 
use of high dose prednisolone in the COBRA therapy gave emotional resistance.  
 
R-T2 : “The dose of prednisolone, as a physician I’d rather start with 20 or 30 mg, it’s 
a matter of feeling, you know, but it feels more comfortable than 60 mg.” 
R-A : “An essential point is simply, do you want to implement this schedule yes or 
no. And my feeling is, I’m just not going to do it. If deep in your heart you are 
not convinced that this is the schedule I’d like to give to my patient, regardless 
of how good the results are, then there isn’t much point to it, if I’m honest.” 
R-T5 : “It’s more the fear, ‘in the doctor’s mind’. The fear lingers a bit, you can’t get it 
out of your head completely.” 
 
Societal implications 
Only one rheumatologist felt that as a doctor he had the obligation towards society to rather 
choose a cheap effective therapy as opposed to an expensive effective therapy.  
 
R-M : “Because I feel we as professionals have a certain responsibility to society; if 
we can achieve the same effect with fewer financial resources we should do 
so.” 
 
Perceived value of scientific evidence 
Scientific evidence was regarded as very important. It was generally accepted that the 
COBRA trial and the BeSt trial showed that COBRA combination therapy is very effective, 
both on the short term and the long term.  
 
R-C : “With this schedule you KNOW that after 5 years there are fewer erosions than 
with sulfasalazine alone.” 
 
However, much discussion focused on components of the COBRA therapy: the effectiveness 
of the combination MTX and SSZ was put in doubt, since a study of Haagsma et al, 1997 
showed that SSZ and MTX in combination are as effective as both drugs alone17. 
Rheumatologists doubted the value of SSZ in the treatment schedule, especially because 
SSZ was maintained as the anchor drug in the original COBRA trial. SSZ was perceived as 
old-fashioned and currently replaced by high dosages of MTX. The dosage of 7.5 mg MTX in 
the COBRA therapy was perceived ineffective. Additionally, they felt there was no evidence 
that a dosage of 20 mg prednisolone would be less effective than 60 mg. 
Even though some rheumatologists saw great advantages, most rheumatologists were not 
convinced that treating their patient with COBRA therapy was the best for them: 
 
R-T9 : “The greatest disadvantage is the feeling one has of doing things that are not 
necessary and that unnecessarily complicate matters. If one is convinced that 
all those 3 things are necessary, then of course one can explain it and create 
a system to make it clear to the patient. But it is more that one isn’t convinced 
that giving this combination in this particular way is really necessary.” 
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Patients 
The patients, mostly with longstanding disease, still remembered that in their early stages it 
took quite some time before the disease had been diagnosed and treatment initiated; they 
recalled having had a difficult period thereafter, experiencing many different types of 
DMARDs. In general, after the diagnosis had been made and the treatment had been 
explained, patients were glad that something could be done about it, and had more faith in 
facing the future. Therefore, patients wanted their rheumatologists to start as actively and 
aggressively as possible with a therapy that would improve their prognosis.  
 
P-C : “I started with methotrexate, 4 tablets, well it gradually became more, and I 
thought ‘give me as much as possible’, because I really revived, wasn’t as 
tired anymore, the pain became bearable and finally went away.” 
 
When the therapy is effective and patients regain quality of life, the desire to decrease the 
number of pills that has to be taken becomes important. 
 
P-I : “I was really happy that I could leave off a medication like that once in a while”. 
 
Two themes were identified: RA treatment: experiences, side effects, fear and future 
expectations and faith in physician. 
 
RA treatment: experiences, side effects, fear and future expectations  
In general, patients, being aware of the negative side-effects of the medication prescribed, 
greatly appreciated all kind of medication for the treatment of RA, because life without 
medication would be very complicated or even impossible 
 
P-F : “I have regained quality of life, while it was completely gone for a long time, so 
I am really happy that I’m alive at this time and that these drugs are available.” 
 
Only a few patients remembered using SSZ. It was not regarded as a very important DMARD. 
Patients who had used it, reported that it did not work very well. The tablet size was no issue 
to them, neither was the large number of tablets that had to be taken: 
 
P-I : “No, no, nothing wrong with that [red: about the size of the tablets]; but it’s 
hard to digest, like ‘there it is’.” 
P-G : “I have no trouble with it at all, at breakfast I just knock them back all at once.” 
 
MTX was a much more widely known drug; a patients’ first introduction to the drug was 
generally perceived as a bit scary, because of the use of MTX in oncology. Opinions about 
the use of MTX varied a lot; some perceived it as being very effective, others as scary and 
uncomfortable because of the stomach pains after intake: 
 
P-F : “I remember, I was terrified, because I had to take corticosteroïds and an 
oncological drug, it was intense.” 
P-C : “It was a miracle drug for me, because I was like a vegetable, and suddenly I 
was jumping around again like the person I thought I was.” 
P-A : “I don’t feel well on MTX; it makes you very tired and also my stomach bothers 
me a lot.” 
 
Prednisolone was associated with negative side effects, all affecting appearance, and this 
was regarded as being a big issue. On the other hand, many patients had experienced great 
improvements on prednisolone and perceived it as being highly effective. Two patients, who 
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experienced the worst side effects of prednisolone over many years, felt it to be a drug they 
could always count on when other drugs failed. 
 
P-I : “In the early 70’s, it gave me a rather bloated face.” 
P-F : “They say that if you use it for long, you gain weight because you feel hungry 
all the time, and indeed I gained 5 kilos, and can’t take them off...” 
P-K : “It’s the only drug that helps. That shows again that it is really a fantastic drug.” 
 
Some patients felt disappointed to not be able to live without it: 
 
P-G : “Because I suffer from osteoporosis, mainly from using prednisone, that is 
corticosteroïds, we tried to completely cut down my prednisone intake, but for 
some reason that didn’t work..” 
 
Fear for medication was based on reading the information leaflet, reactions from the social 
circle and on witnessing negative side effects of the drugs in other patients: 
 
P-C : “Yes, and your social circle reacts strangely in my opinion: ’WHAT, 
prednisone? Don’t start with that!...” 
P-J : “My orthopaedist said: ‘arthritis patients actually have 2 diseases, that is 
arthritis and methotrexate’; I have always remembered that. If a doctor talks 
this way about a drug...” 
P-E : “Yes, on our holiday, someone was injected with MTX on Thursday and he 
was sick from it all of Friday and Saturday, well, I thought, ‘I’ll never take that 
rubbish.” 
 
The main expectation of treatment was equal to all patients: less pain, more functionality and 
an improved quality of life. Work and a social life were very important determinants of quality 
of life. Patients mainly focused on quality of life in the near future, but the limitation of further 
bone damage was also regarded as being important. 
 
P-C : “What I expect is, the pain has to go, and the terrible fatigue, and then I still 
don’t know what to expect in terms of deformed hands and so on...” 
P-F : “Most important is that you can join in on things like this meeting again, that I 
could go back to work, maybe only for 3 hours a day, but I felt that I got a 
piece of my life back.” 
 
Trust in physician  
The relationship between the rheumatologist and the patient was regarded as being important 
to patients.  
 
P-H : “My rheumatologist told me: ‘hang on to me, we’re really watching over you 
very carefully’. That was very reassuring for me. It gives you some faith after 
all, because you really have no other choice.” 
P-B : “You shouldn’t talk about it with others; you just need a doctor you can trust, 
who is an expert. I never listen to those people [red: other people with advice 
about RA treatment] any more, I don’t ask, I don’t listen. I say, I have a good 
doctor, thank you very much.” 
 
An arthritis nurse was also regarded as supportive and valuable in case of uncertainties; 
 
P-G : “If I do have questions in between, I can call my arthritis nurse, who in turn will 
contact my rheumatologist. It is great to be sure of that.” 
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DISCUSSION 
This qualitative study shows a large discrepancy between what patients actually feel about 
COBRA therapy (mostly positive) and what rheumatologists think they feel (mostly negative). 
Together with perceived practical problems in prescribing the therapy and personal emotions 
on the part of the rheumatologists, these are clues to explain why COBRA therapy is so rarely 
prescribed. 
 
Rheumatologists were positive about the effectiveness of COBRA therapy, but highly 
concerned about their patients’ possible negative reaction to the large amount of pills to be 
prescribed. In addition, rheumatologists perceived lack of time explaining and prescribing 
COBRA therapy and felt uncomfortable prescribing high doses of prednisolone.  
On the other hand, patients were positive about an aggressive combination therapy such as 
COBRA therapy, and they had no qualms taking many pills if this would give immediate relief 
or might improve their prognosis. Patients associated prednisolone with negative side effects 
(especially affecting looks), but they were also aware of its benefits and the need of 
prednisolone in rough times. A decrease in the amount of pills after intensive treatment was 
highly appreciated.  
 
In conceptualizing why the difference between doctors and patients occurred, two major 
issues came up: firstly, it was found that doctors feared to fail in the eyes of their patients in 
prescribing such a disagreeable therapy. Secondly, it appears that rheumatologists formed 
their opinion and feelings concerning COBRA therapy overlooking the initial burden of the 
disease. Their concerns towards the therapy appeared more in line with the desires of a 
hypothetical patient in a later stage of the disease, but not with the desires of newly 
diagnosed patients for whom COBRA therapy is intended. Patients stated they based their 
opinions on their own experience at the start of the disease and concluded that taking a lot of 
pills felt a whole lot better than the pain and constraints they were facing with the disease. So, 
at the start of the disease, patients just want relief of their pain and return to life the way it 
was. Their major concern about the therapy is that it has to work, agreeable or not. Other 
concerns, such as decreasing the amount of pills, are for later.  
  
Several studies have reported differences in perceptions between rheumatologists and 
patients18,19. In rheumatology, differences between assessments of physician global and 
patient global are well known. The rheumatologist might observe a large improvement in joint 
count and ESR, whereas the patient fails to experience improvement in pain or global well 
being20,21. The importance of the patient’s perspective is increasingly recognised, as can be 
seen in the success of the patient perspective program in the OMERACT (Outcomes in 
Rheumatology) initiative. As an example, the OMERACT community has accepted that 
fatigue is a relevant and important symptom in RA and should be measured in all trials22,23. 
Our findings reinforce that also in case of prescribing COBRA therapy, rheumatologists 
should take note of the real patient perspective on COBRA therapy as described in this article 
and not act according to their own preconceived opinion of that perspective. 
 
Another important factor that determines rheumatologists’ reluctance towards the use of 
COBRA therapy for early RA is the workload. Dutch rheumatologists have only 10 or 15 
minutes to explain the diagnosis and start a treatment; it is very difficult to explain the patient 
about the ins and outs of all the drugs involved in this short time. 
 
It is remarkable that only one rheumatologist mentioned the cost-effectiveness of COBRA 
therapy. Former research showed that COBRA therapy provided additional disease control at 
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lower or equal cost compared to SSZ8,9 and it is obviously cheaper then most new alternative 
drugs. Still, cost-effectiveness was not an issue for rheumatologists. Key opinion leaders 
potentially have an important role in promoting conventional treatment regimens and raising 
cost awareness. Their actual role could be an interesting area for future research. 
 
Patients routinely associate prednisolone with an unfavourable appearance; a problem faced 
daily by rheumatologists. However, our study shows that, although patients experience 
negative side-effects of the use of prednisolone, they are also highly aware of its strong 
positive effect, something to count on when all else fails. The latter is largely overlooked by 
the rheumatologists.  
The BeSt study also reported a negative perception of patients towards prednisolone: a 
questionnaire exploring preferences of patients 2 years after the trial (retrospectively) reported 
that 38% of all patients had hoped not to be randomised into the COBRA arm24. This 
perception was much less prominent for the patients who actually received prednisolone 
during the trial. Possibly this same effect is seen in our study; because all the participating 
patients had experience with RA treatment and many of them with prednisolone, their 
negative perceptions towards this drug are probably less profound than without such 
experience. In contrast, most BeSt patients expressed preference for infliximab. However, we 
feel this comparison is hard to interpret: the questionnaire contained leading questions and 
was administered post-hoc, as the authors admit in their discussion. 
 
A limitation of this study is that the patients participating in the group discussion were already 
very experienced, with average disease duration of 22 years. These patients appreciated the 
benefit of early and active treatment, because they themselves were treated in a time when 
therapy was not as advanced as it is now. On the other hand, these patients, including the 
active members of the national patient rheumatic association, were of great value to the 
discussions, because they have daily contact with new inexperienced patients in advising and 
helping them with uncertainties and were thus very well able to understand and express the 
patient position. Also, practical concerns limited the possibility of patient data collection so this 
data may be incomplete. 
 
This study shows that practical and emotional constrains make rheumatologists reluctant 
towards prescribing COBRA therapy in their own practice. Information about patients’ 
opinions on COBRA therapy needs to be disseminated among rheumatologists. We are 
working to improve uptake by specific information materials, pre-printed prescription orders, 
training of the arthritis nurse and by the dissemination of research findings as presented in 
this and other papers. 
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SUPPLEMENTARY DATA 
During the two focus group discussions and interview with patients, a short scenario was 
presented to all patients; they were asked to imagine that they came to the rheumatologist for 
the first or second time with their complaints and that the COBRA therapy was explained to 
them.  The scenario was read out loud as if the rheumatologist was sitting in front of them. 
This supplementary file presents the reaction of patients to this scenario. 
 
  
COBRA therapy: scenario during focus group discussions and interview with patients 
 
This afternoon you are visiting the rheumatologist in the VU University Medical Center for the 
first time. Your general practitioner has sent you here because of complaints in your hands 
and feet. First, the rheumatologist asks you about your complaints. Then, a physical 
examination follows. Finally, your joints are checked for swelling, tenderness and functionality. 
After this examination, the rheumatologist tells you that you probably have rheumatoid 
arthritis. He asks for laboratory tests and radiographic images of the joints and prescribes 
NSAIDs to you. After two weeks, you come back. Your rheumatologist tells you that the 
additional research has confirmed the diagnosis. He explains to you that there is a lot that can 
be done about it. In your case, the preferred therapy is COBRA therapy. The rheumatologist 
explains to you what this therapy is all about: 
 
“COBRA therapy is a treatment in which three drugs are combined to suppress disease 
activity as rapidly as possible. Research has shown that this is very important for the 
development of the disease in the future. All three drugs are standard in the treatment of 
rheumatoid arthritis. But research has shown that this combination is not only very powerful, it 
is also well tolerated. That is why I prescribe three drugs to you: Firstly, the drug 
methotrexate. This is a drug that you take once a week. Secondly, I prescribe sulfasalazine. 
You take this drug twice a day, after a step up period of 2 weeks. Finally, I prescribe 
prednisolone; you get a high dose of this drug during the first week and then we quickly step 
down. This means that you take 60 mg a day during the first week, 40 mg a day during the 
second week, and we step down this way to 7.5 mg a day during the 7th week. 
The treatment works very rapidly, and will last for 28 weeks. Then, we try to stop one or more 
drugs in a gradual manner. You have to count on continuing with at least one of the three 
drugs, otherwise the disease will come back. You will notice that you don’t need the NSAIDs 
(and stomach protectors) anymore, so the number of pills also decreases. The inflammation 
has cost the body a lot of energy and many people have not noticed they lost weight since the 
illness started.  A powerful treatment like COBRA will increase your weight with a few kilos. 
That is not a side effect. 
Although the COBRA combination is very well tolerated, all drugs have side effects. It is a 
long list, but most are rare. For methotrexate and sulfasalazine the most common side effects 
are nausea and a heavy feeling in the stomach, and problems in the liver, lungs and blood. 
Hypersensitivity (allergy) also occurs, but is rare when prednisolone is also taken. For 
prednisolone, the side effects are (usually temporary) increase of weight, amongst other 
things because of fluid retention and an increase of appetite; agitation; increased blood 
pressure and blood sugar; and if used for a long time bone loss and an increased risk of 
infections. For more information you can read the information booklet. 
To minimize the chance of side effects of methotrexate and prednisolone, you will get a 
vitamin package containing folic acid, calcium and vitamin D. In your case, extra bone 
protection is (not) needed. 
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As I said earlier, COBRA therapy works fast; within hours of taking the first tablets the 
symptoms will decrease. I would like to see you after two weeks; I expect your arthritis to be 
very calm, but especially in the beginning it is important to see if you do not develop any side 
effects. Can you give blood and urine a few days in advance? Then I will have the results 
when you come.” 
 
 
Reactions of patients to the scenario: 
 
The one COBRA patient acknowledged that this was how her treatment started two years 
back: 
 
COBRA 
patient 
: “This is how I experienced it.” 
Interviewer : “And what was your reaction to it?” 
COBRA 
patient 
: “Hopeful of course. And when I felt it was quickly helping me, with those 
stiff hands, I felt revived” 
 
Patients appreciated the heavy start with a strong therapy and felt it to be very different from 
the way it was done in the past. They get really enthusiastic about it, they think they might try 
it themselves: 
 
P-E : “Yes good, really good, a very different approach then in the old days.” 
P-B : “Yes, if they say it might have some side effects, some nausea, OK, we’ll see. I 
would have felt so enthusiastic if they had told me this the first time I came. It’s 
different of course when you have just heard that you’ve got rheumatoid arthritis, 
but if they say ‘we’ve got something here and that will work really well’, I would 
have been overjoyed.”  
P-B : “Even now, I would be really happy to hear that this could probably suppress the 
disease in one fell stroke” 
P-A : “yeah, of course” 
P-B  “Yes, I didn’t know exactly the composition, [red: of COBRA therapy] but I’m a 
big fan. If the complaints decrease, then I think, why aren’t they all cheering?” 
P-C : “Yes, it suits my character, like, get right to business. I’m definitely a proponent 
of a tough approach, especially because my rheumatologist told me that you can 
prevent a lot of damage and degeneration in the long term.” 
Inter      
viewer: 
 
“We have also had this type of focus group with rheumatologists, and they prefer 
not to prescribe this therapy. They are aware of the effectiveness and benefits, 
but they also think that the patient will not appreciate it.” 
P-B :  “I think that that is more the opinion of the rheumatologists than that of the 
patient. If they explained to me what it is for and that you can prevent damage 
with it, well, then you will want to use it! Then it doesn’t matter if you have to take 
something once a day or three times a day. No, then you’ll want it.” 
P-H :  “They are all busy with the TNF now, if this works so well, equal to TNF, I would 
say let’s go for it.” 
P-B : “Yes, let’s try that. I was also thinking, leave it all and start all over again.” 
 
Patients appreciated that the major fears and side effects of the drugs were clearly named in 
the case study (MTX comes from oncology prednisolone might increase your weight up to 
mean 3 kg). 
 
P-A : “About the methotrexate, because many people that read this and then hear it is 
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a cancer drug. They should tell you about that beforehand, the scariest stories 
go round about that.” 
P-E : “Yes! Because then you’re better prepared, if someone says ‘you know what 
you’re taking, they also use that in cancer patients!’” 
P-B : “I feel that all the scary stories and disadvantages, also of prednisolone, that 
they should be mentioned during the first meeting.” 
P-C : “Well I think that if the rheumatologist explains it very well, what the 
consequences could be, so you’re prepared, I think that’s good. In our hospital, 
you’re send to the arthritis nurse who explains about the cancer connection, just 
so you are warned before you read the package insert. So you don’t come 
home thinking, Oh Lord, what do I have to take now.” 
 
They acknowledged that it would be heavy for a ‘new’ RA patient to be confronted with all this. 
They advised to explain to the patients about the damage that can be prevented; so they will 
understand that potent therapy is best in the long run. 
 
P-H : “First it’s panic, because its really a burden to read this. Because, wow, do I 
have to use all of this?” 
P-B : “Rheumatoid arthritis, people think, then you’re old and in a wheelchair. That’s 
you’re future. That’s what you think at first: end of my life. Then you come back 
two weeks later, then the drugs come up, and you think: ‘something can be 
done’. That makes you feel better.” 
P-H : “Let’s be honest, if I would come for the first time and would hear all this, 
nausea, heavy feeling in the stomach, all that side-effects that’s ok. But then 
liver, lungs, blood, well, that would scare me.” 
P-B : “That you have to use such heavy medication for those light complaints, some 
pain in my wrist or feet but nothing more for the moment. Then you come in and 
think, ‘I have to take all that? Whohh, always? Yeah, I feel that’s heavy.” 
P-C : “I feel that rheumatologists should stress the fact that the damage that is done 
cannot be reversed. And I think you should use that in your story, like ’its 
important to take rapid and tough measures, to prevent the damage from 
occurring’. I think that if you explain that to a patient and document it well, it’s 
still scary, but that they will see the point, because the damage cannot be 
repaired.” 
P-G : “The first strike is half the battle I think.” 
P-G : “I think you should also stress that the deformations occur during the first years. 
Because we don’t only want to take care of the disease activity, but also of the 
joint damage, which is irreversible. I think that THAT will convince most people.” 
P-F : “Show it on the x-rays, those ‘moth-eaten’ joints.” 
 
Patients felt that this therapy would be accepted, and that the real questions would come 
when it was working, and people would think of taking less drugs. 
 
P-C : “I think that even if they write it in a more scary way, I think people don’t really 
think about that. I think the real questions come up when you’re using the meds 
for a while and when you feel some improvement. Then you start thinking, but 
what can I take off, because its all garbage, right? That’s how I see it. But when 
you’re so down, sick, tired, worn off, you’ll take anything.” 
P-TA : “The positive thing about your scenario is that you clearly tell that you can 
expect a fast result; someone who comes in with a lot of pain, just wants 
something that will work fast, because that pain is new to them. And what I also 
find very positive is that you directly point out that you will step down, that you 
will lose two drugs in the future, so that you can continue with one drug  on the 
long term.” 
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Patients advised to put all the information on paper, so you would not forget it later and they 
appreciated the help and guidance of an arthritis nurse. 
 
P-B : “If I hear that, it goes in one side and out the other. You’re only thinking, oh how 
terrible that I have this, that I have to use all this; put it on paper.” 
P-TA : “Yes, I remember the first time you have to take unknown drugs, it is really 
unpleasant, especially a combination. For that reason I was hospitalised. I was 
just a student that time. So I think guidance is very important. I think, practically 
speaking, the rheumatologist does not have time for this; this is a job for the 
arthritis nurse.  And I would try not only to give patients the opportunity to call 
the arthritis nurse, but to let the arthritis nurse call the patient weekly once. And 
maybe it is nice to, during the first consultation, to NOT come up with information 
about wheelchairs or scary futures, but more positive; internet sites of the 
arthritis foundation with education material. So during the second consultation 
the patient is better informed.” 
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ABSTRACT 
 
 
OBJECTIVE 
COBRA combination therapy is effective for the treatment of rheumatoid arthritis (RA), but 
long term safety is unknown. This study evaluates survival, comorbidities and joint damage in 
the original COBRA trial cohort. 
 
METHODS 
In the COBRA trial, 155 early RA patients were treated with sulfasalazine monotherapy (SSZ 
group) or a combination of step-down prednisolone, methotrexate and sulfasalazine (COBRA 
group). The current 11-year follow up study of the COBRA trial invited all original patients and 
performed protocollized scrutiny of clinical records, questionnaires, physical examination, 
laboratory and imaging tests. 
 
RESULTS 
152 out of 155 patients yielded at least partial data. Treatment strategy, disease activity and 
functional capacity did not differ between the groups. After mean 11 years follow up, 18 (12%) 
patients had died, 6 COBRA patients and 12 SSZ patients, hazard ratio 0.57 (95%CI: 0.21-
1.52). Treatment for hypertension was significantly more prevalent in the COBRA group 
(p=0.02) with similar trends for diabetes and cataract. Conversely, hypercholesterolemia, 
cancer and infection showed a trend in favour of COBRA. Other comorbidities such as 
cardiovascular disease and fractures appeared in similar frequency. Radiographic findings 
suggest as a minimum sustained benefit for COBRA therapy, i.e. difference in joint damage 
but similar subsequent progression rates after 5 years. Imputation to compensate for selective 
dropout suggests increasing benefit for COBRA, i.e. difference in yearly progression rates 
similar to that seen in the first 5 years of follow up. 
 
CONCLUSION 
After 11 years, initial COBRA combination therapy resulted in numerically lower mortality and 
similar prevalence of comorbidity compared to initial SSZ monotherapy. In addition, lower 
progression of joint damage suggests long-term disease modification. 
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INTRODUCTION 
The COBRA study, (COmbinatie therapie Bij Reumatoïde Artritis), was a double blind 
randomized controlled trial in patients with early rheumatoid arthritis (RA) that compared the 
combination of three traditional disease-modifying antirheumatic drugs (DMARDs) 
(sulfasalazine (SSZ), methotrexate (MTX), and prednisolone) with monotherapy (SSZ). It 
proved COBRA therapy to be a rapidly effective treatment of RA1 including a sustained 
decrease of radiologic progression after mean 4.5 years follow up2. A subsequent trial 
showed COBRA therapy to be as effective as initial combination therapy of high-dose MTX 
with infliximab3,4. Despite this, we showed that Dutch rheumatologists are reluctant to use 
COBRA in their clinical practice5, mainly due to practical and emotional constrains as well as 
concerns over long-term safety of high dose prednisolone6. Worldwide the use of 
prednisolone in RA is still a topic for debate7. 
In the context of an effort to improve uptake of COBRA in general rheumatology practice, we 
conducted a study on the long-term safety of this regimen by studying survival and 
comorbidity in the original COBRA trial cohort. In addition we studied whether the benefit on 
radiographic progression present at 5 years was sustained over a longer period. 
 
METHODS 
The COBRA-cohort 
From 1993 to 1995, 155 patients with early RA entered a randomized, double blind trial 
comparing COBRA combination therapy to SSZ monotherapy. Details of the initial trial and of 
the 5-year follow up have been reported previously, key demographics are summarized in 
Table 11,2. In summary, inclusion criteria were: a diagnosis of RA (American college of 
Rheumatology (ACR) criteria) with a duration of 2 years or less; ≥6 swollen joints and 
presence of at least two of the following: ≥9 tender joints; morning stiffness ≥45 minutes; 
erythrocyte sedimentation rate (ESR) ≥28mm/h. Patients previously or currently treated with 
any DMARD except antimalarials were excluded.  
COBRA step-down combination therapy comprises SSZ (2 g/day), MTX (7.5 mg/week) and 
an oral pulse of prednisolone, starting with 60 mg in the first week and tapered to 7.5 mg in 
the 7th week. At 28 weeks, prednisolone is tapered and withdrawn and after 40 weeks, MTX is 
withdrawn. Patients in the SSZ group received SSZ (2 g/day) and placebo MTX and 
prednisolone. All patients received folic acid (1 mg/day), calcium (500 mg/day) and if needed 
25-hydroxyvitamin D (400 IU/day). Patients experiencing a disease flare during or after 
tapering of a drug restarted treatment with the drug that was most recently withdrawn. After 
the protocol period of 56 weeks, treatment decisions were made at the discretion of the 
treating rheumatologists. All patients were invited for follow up by their current rheumatologist. 
The general practitioner was asked to invite patients without a rheumatologist to participate at 
the nearest hospital. Assessments and data collection were blind to the original treatment 
allocation. All participating patients gave their written informed consent; this study was 
approved by the medical ethical committee of the VU University Medical Center. 
 
Outcome measurements 
Disease activity and patient reported health outcomes; trained research nurses performed the 
joint counts to calculate the 28-joint disease activity score (DAS28), with remission at 
DAS28<2.68. Visual analogue scales measured pain and fatigue, and the Health Assessment 
Questionnaire (HAQ)9, SF-3610, and EuroQol11 measured functional ability and health status 
respectively. 
Laboratory measurements included ESR, CRP and cholesterol (total, LDL and HDL). 
Survival and comorbidities; clinical records (and the general practitioner where necessary) 
were queried for survival, including information on date and underlining cause of death. 
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A protocollized scrutiny identified major comorbidities. For a list, see APPENDIX I. Dual-
energy x-ray absorptiometry (DEXA) measured changes in bone mass (BMD) in the 
anteroposterior lumbar spine at L2-L4 and the femoral neck. Two readers (WL, BD) unaware 
of the trial allocation graded radiographs of the thoracic and lumbar spine for vertebral 
deformities (Th4–L5, Genant criteria)12. 
Radiographs; as follow up of radiographs of hands and feet was complete for up to 5 years, 
the current study collected all available subsequent radiographs, including one made for this 
study. Two independent assessors scored digitally converted images of 2, 5, 8 and 11 years 
of follow up according to the Sharp/van der Heijde method13,14. Assessors were blinded for 
group allocation but aware of time sequence; improved scoring was allowed. Their agreement 
on the change between 5 and 11 years (intraclass correlation coefficient) was 0.82. Missing 
data were linearly interpolated between available assessments. Results are reported as the 
mean of the two observers’ scores. To compensate for differential dropout, an extra dataset 
was made that replaced missing values up to 11 years by values imputed from individual 
progression rates of patients between 0 and 5 years follow up.  
Drug use; drug treatment was documented from 56 weeks (end of trial), facilitated by the 
presence of earlier follow up data. The use of DMARDs and biologicals was registered as 
yes/no; use of oral prednisolone was calculated as mean and cumulative dose following a 
protocol (see APPENDIX II). Patients completed a questionnaire on lifestyle, comorbidities 
and drug use, with special focus on prednisolone and biologicals. 
 
Statistical analysis 
T-tests and continuity-corrected Pearson chi-square tests analyzed differences between 
treatment groups where appropriate, without correction for multiple tests. Cox regression 
analyzed survival; data were censored April 1, 2006. Survival was also compared to a 
reference sample of the general population of the Netherlands, matched for age and sex15. 
Generalized Estimating Equations (GEE) analysis with an exchangeable correlation structure 
was applied to analyze progression of joint damage on radiographs in years 5, 8 and 11. 
Significance was reached at p<0.05. All statistical analyses were conducted using SPSS for 
Windows, version 15.0. Patients who died during the follow up period contributed data up to 
the moment of death.  
 
RESULTS 
The original COBRA trial included 155 patients; 76 received COBRA therapy and 79 SSZ 
only.  
For survival follow up is almost complete with only 3 of 155 patients completely untraceable. 
Reasons for 20 patients to refrain from full participation comprised: health problems (n=3), not 
seeing a rheumatologist anymore and unwilling to participate (n=5), one center not 
participating (n=5) and unspecified (n=7). In some of these 20 patients data could still be 
gathered from available material. Radiographs at 11 years were available for 112 patients and 
2 or more radiographs were available for 146 patients. Follow up of comorbidities and drug 
use in clinical records is complete for 146 out of 155 patients, with 2 patients missing in the 
COBRA group and 7 in the SSZ group. Vertebral fractures could be studied for 50 COBRA 
patients and 43 SSZ patients and DEXA was measured in 47 patients in both treatment 
groups. Apart from the 3 untraceable patients, we were unable to follow up on any outcome 
other than death of a further 6 patients (3 COBRA, 3 SSZ). Of 9 patients, only comorbidities 
were documented, but no new data could be gathered (2 COBRA, 7 SZZ).  
 
General health characteristics 
Mean age of patients at follow up was 60 years, with more females in the COBRA group (68% 
v SSZ 52%; Table 1). Functional capacity and disease activity between the groups was 
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similar: mean (SD) HAQ-score 1.02(0.69) v 0.91(0.65); DAS28 3.05(1.2) v 3.07(1.3) with 39% 
of patients in remission in both groups. The patients lost to follow up at 11 years (25 SSZ 
patients and 16 COBRA patients) had a significantly higher HAQ at 5 years follow up. Utility 
scores (EQ-5D) were also similar: 0.72(0.2) v 0.74(0.2). Scores on the SF-36 were also 
similar, and all subdomains except mental health were well below population norms in the two 
groups (data not shown). 
 
Survival 
After mean 11 years follow up, only 6 patients had died in the COBRA group compared to 12 
in the SSZ group. Adjusted for age, the hazard ratio for COBRA compared to SSZ was 0.57 
(95%CI: 0.21-1.52, p=0.26). Additional adjustment for sex yielded similar results (Figure 1).  
Causes of death in the COBRA group were: 2 cancer (adenocarcinoma, lung); mesenteric 
thrombosis; pulmonary fibrosis; 2 unknown. Causes of death in the SSZ group were: 6 cancer 
(lung, colon, pancreas, acute myeloid leukemia, ovary, adenocarcinoma); 2 cardiovascular 
disease (myocardial infarction, circulatory failure after hip surgery); 1 obstructive pulmonary 
disease; 3 unknown.  
 
Comorbidity 
Major comorbidity was similar in both groups. Specifically, cardiovascular events did not occur 
more commonly in the COBRA group (Table 2). However, hypertension was significantly 
more prevalent in the COBRA group, and there were similar trends for diabetes and cataracts. 
In contrast, hypercholesterolemia, cancer and infection showed a trend in favor of COBRA.  
Prevalence of osteoporosis was also similar in both groups: clinical fractures, radiographic 
vertebral fractures, and bone loss were all similar. Prevalent vertebral deformities (mostly 
thoracic) were found in 11 of 50 (22%) patients in the COBRA group vs 9 of 43 patients (21%) 
in the SSZ group. Mean bone loss at the spine and femoral neck since inclusion was -5.2  
(14.3) and -11.1% (13.9) in the COBRA group and -4.1 (12.0) and -11.8% (12.4) in the SSZ 
group. Osteoporosis based on the DEXA measurement at 11 years (T-score <-2.5 in spine or 
hip) was seen in 5 COBRA patients and 9 SSZ patients. 
 
 
*  Mean (SD) or count (%) unless noted otherwise 
†  For 11 years follow up: all patients, except 18 dead, 3 missing 
‡  62 COBRA patients, 52 SSZ patients 
§  0 (no active disease/pain/fatigue) to 100 (the worst possible active disease/pain/fatigue) 
||  Patients with available baseline radiographs/11-year radiographs; combined treatment group n=74/60, sulfasalazine  
  group n=75/52 
n/a not available 
Table 1   Baseline patient characteristics, at 0 and 11 years after the COBRA trial 
 Baseline 11 year follow up 
Characteristic* COBRA 
(N=76) 
SSZ 
(N=79) 
COBRA 
(N=69) 
SSZ 
(N=65) 
Age (years) †  50 (12) 49 (12) 61 (12) 60 (12) 
Women † 50 (66%) 41 (52%) 47 (68%) 34 (52%) 
Disease duration (months) median 
(range) † 
4  
(1-24) 
4  
(1-23) 
142  
(131-154) 
140  
(131-155) 
DAS28 score ‡ 5.9 (1.0) 5.7 (1.0) 3.0 (1.2) 3.0 (1.4) 
Physician VAS ‡ § 53 (24) 51 (22) 17 (17) 16 (15) 
HAQ score ‡ 1.5 (0.1) 1.4 (0.1) 1.0 (0.7) 0.9 (0.7) 
Pain VAS ‡ § 55 (21) 54 (22) 28 (23) 25 (23) 
Fatigue VAS ‡ § n/a n/a 31 (25) 27 (28) 
Erosions on hand or foot radiographs || 55 (74%) 59 (79%) 52 (87%) 42 (81%) 
Positive IgM rheumatoid factor   59 (78%) 57 (72%) n/a n/a 
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Drug treatment 
After the trial period COBRA patients tended to be on prednisolone more frequently and use it 
for longer periods which resulted in a somewhat higher mean cumulative dose (see 
APPENDIX II); none of these differences were significant. Likewise, the proportion of patients 
treated with MTX or biologicals was slightly (but not significantly) higher in the COBRA group. 
 
Radiography 
In the patients available for study, on initial examination damage progression appears similar, 
with median damage in the COBRA group even slightly higher than the SSZ group at 11 
years (Figure 2). GEE analysis suggests scores in both groups increase by 2.4 points per 
year with the COBRA group 4.2 points lower than the SSZ group at every time point. 
However, the interpretation of the results is hampered by differential dropout: more patients in 
the SSZ group dropped out (12 died, 15 lost to follow up) and these patients had more 
damage at their last available measurement (51, median 25) than the COBRA patients that 
dropped out (6 died, 11 lost to follow up; score mean 23, median 8). This is seen by the 
distribution of the last available scores in Figure 2. When data of the patients that were lost to 
follow up are imputed up to 11 years according to their individual progression rate in the first 
follow up period (1 to 5 years2), the GEE model shows a significant difference between the 
treatment groups of 3.1 points per year in favor of the COBRA group, consistent with the 
results in the first 5 years (p=0.03). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  11-year survival after the COBRA trial. SSZ (lower line) in dark grey, healthy Dutch  
control population (middle line) in light grey, COBRA (upper line) in black. 
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Table 2   Comorbidities in 11 years of follow up 
Comorbidity COBRA SSZ 
 No (%) Events * No (%) Events * 
Cardiovascular events 13 (17) 14 (19) 
   - Myocardial infarction 5 (7) 5 (7) 
   - Stroke 5 (7) 1 (1) 
   - Angina pectoris 5 (7)   8 (11) 
   - Heart failure 1 (1) 3 (4) 
   - Peripheral vascular disease 1 (1) 0 (0) 
Hypertension 18 (24)   8 (11) 
   - Treated   18 (24) †   6 (8) † 
   - Untreated 0 (0) 2 (3) 
Hypercholesterolemia   6 (8) 12 (17) 
   - Treated 4 (5) 11 (15) 
   - Untreated 2 (3) 1 (2) 
Diabetes mellitus 7 (9) 1 (1) 
Clinical Fracture   7 (10)   8 (11) 
Osteoporosis (T-score<-2.5 at spine and/or hip)   8 (11) 11 (14) 
   - During follow up period ‡   7 (10)   8 (11) 
   - At 11 year DEXA §   5 (11)   9 (18) 
   - At 11 year spine X-ray || 11 (22)   9 (21) 
Avascular bone necrosis 0 (0) 0 (0) 
Infection   7 (10) 16 (22) 
   - With hospital admission 2 (3)   8 (11) 
   - Without hospital admission 5 (7)   8 (11) 
Gastrointestinal events 5 (7) 3 (4) 
Glaucoma 2 (3) 1 (1) 
Cataract   7 (10) 2 (3) 
Cancer 6 (8) 10 (14) 
* Percentage of events calculated as the number of patients with one or more event per number of patients in the follow 
 up group for who clinical records could be evaluated, unless stated otherwise (totals may differ due to rounding) 
† p<0.05 
‡ recorded if a DEXA measurement was available in the clinical record 
§ DEXA measurements at 11 years were available in 94 patients, 47 in each treatment group 
|| Prevalent vertebral deformities (mostly thoracic) at 11 years, measured by radiographs of the thoracic and lumbar 
 spine, were found in 11 of 50 (22%) patients in the COBRA group vs 9 of 43 patients (21%) in the SSZ group 
 
 
DISCUSSION 
This 11-year follow up study strongly suggests that brief and intensive combination therapy 
that includes an oral pulse of glucocorticoids has a risk profile similar to that of other 
antirheumatic strategies. Especially glucocorticoids administered in this fashion do not appear 
to carry an unacceptable risk of long-term consequences. In fact, in the COBRA group actual 
mortality was lower, and cardiovascular and other major comorbidities similar to that in the 
SSZ group. Increases in the prevalence of hypertension and diabetes were offset by a 
decrease in hypercholesterolemia. Prevalence of osteoporosis was also highly comparable. 
Many commonly reported side effects of prednisolone16 were not seen at all in our study. 
Moreover, after 10 years of therapy at the discretion of the treating physician, benefits on the 
disease itself, as previously demonstrated in damage progression after 5 years2 appeared to 
be maintained and perhaps even continued to increase after COBRA therapy, depending on 
how one deals with the selective drop-out. Recently Verschueren and colleagues 
demonstrated the feasibility of COBRA therapy in daily practice17. Given these and former 
published data1,2;5,6;18,19, we feel COBRA therapy is effective, cost-effective, feasible and safe 
to use as treatment in early rheumatoid arthritis. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2a  Total Sharp/van der Heijde radiographic damage scores after the 
COBRA trial. Boxes show inner quartiles, medians as thick bar, means as thin 
bar, and 10%-90% percentiles as whiskers; SSZ in white, COBRA in grey. 
Last available score of patients lost to follow up (dots) show patients dropping 
out of the SSZ group have higher damage scores before dropping out. The 
lines represent the GEE model that most closely matches the available data 
(SSZ light, COBRA dark grey). 
Figure 2b  Total damage scores (boxplots) with imputation of missing data at 8 
and 11 years based on individual progression rates recorded between 0 to 5 
years (SSZ in white, COBRA in grey). The lines represent the GEE model that 
best matches this data (COBRA in dark grey, SSZ in light grey). 
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A strength of this study is the high percentage of patients with at least partial follow up. 
Especially the survival analysis, with only three patients declared missing, was very complete, 
giving a reliable result of mortality in our cohort. The 40-50% reduction in mortality risk of 
COBRA is remarkable, especially considering the relatively low overall mortality rate in our 
study. Although our sample size was too small to exclude a chance finding, the converse - an 
increased mortality due to COBRA - has become exceedingly unlikely. Kroot et al studied 
mortality in an inception cohort of patients with recently diagnosed RA followed up for 10 
years. They found a mortality rate of 16% in their inception cohort, compared to 11% in our 
cohort of trial patients; as our patients had active disease, we would expect them to have an 
increased mortality risk20. Like us, Kroot et al found no increased mortality in patients with RA 
compared to the general Dutch population, in contradiction to most studies indicating an 
increased mortality risk21-23. 
In comorbidity, the only significant difference between the two treatment groups was the 
increased prevalence of treated hypertension in the COBRA group. The prevalence of 
hypertension and other comorbidities was identified by chart review and use of medication 
during the follow up period. Clearly, this method has its limitations, such as underreporting or 
selective overreporting in patients treated with the COBRA regimen (expectation bias). For 
instance COBRA patients could have been more frequently checked for hypertension 
because they received a high dose prednisolone in the past, as compared to the sulfasalazine 
patients.  
Another potential point of concern is the bone density data. Bone scanning apparatus may 
have changed over the years, affecting reliability of the change scores. However, this should 
not bias the comparisons between groups, as this would be a center effect and patients were 
stratified for center on randomization. 
The findings on cardiovascular morbidity are highly interesting. The lower mortality and similar 
rates of cardiovascular disease, despite some indication of increased hypertension and 
diabetes mellitus in the COBRA group, suggests that this COBRA regimen including an oral 
pulse of prednisolone has no additional long-term side effects in the setting of chronic 
antirheumatic therapy that includes low-dose glucocorticoid therapy in patients with more 
severe forms of RA.  
Confounding by indication is a well known problem in observational studies that have found 
increased cardiovascular risk in RA patients treated with glucocorticoids. In these studies, 
glucocorticoid use is often a marker for severe disease with its concurrent comorbidity24. In 
our study, glucocorticoid use in the follow up period tended to be higher in the COBRA group 
(52%), although the SSZ group also received prednisolone during follow up (37%). Of note, 
these percentages are still lower than the 66% ‘ever users’ reported by Caplan et al in the 
US7. The use of prednisolone during follow up in both treatment groups makes it impossible to 
judge which side effects are glucocorticoid induced and which are not. Obviously a larger 
sample size and a longer follow up period would make these conclusions more robust. 
However, for side effects and comorbidity that occur frequently the numerical survival benefit 
combined with the lack of further important differences in comorbidity between the groups is 
highly reassuring. 
The main objective of this study was safety, given the persistent concern in the rheumatology 
community over the long-term safety of the COBRA regimen. However, we could not resist 
the temptation to also look at the radiographs and found the proper analysis of such data to 
be complex. 
The analysis of radiographic progression has limitations inherent in a long-term follow up 
study. Patients with the poorest prognosis (and highest progression rates) preferentially 
dropped out of the SSZ group, artificially improving the prognosis of the patients remaining 
available for follow up. Nevertheless, the model most closely describing the available data still 
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shows a stable difference between the treatment groups of 4.2 Sharp/van der Heijde points 
every year. If we impute the progression of the patients that were lost to follow up with the 
best estimation of their real progression rate, there is a sustained and significant difference 
between the groups in yearly progression rate of 3.1 points per years in favour of COBRA. 
Note that this benefit cannot be solely ascribed to the trial treatment. Importantly, treatment 
strategy after the one-year trial was uncontrolled, in contrast to more recent trials. As noted, 
patients in the COBRA group received somewhat more glucocorticoids and biologics in the 
follow up period. The rheumatologists treated the patients to achieve a disease activity level 
that matched treatment options and expectations at that time. In our view, this mostly explains 
the numerical differences in treatment intensity and similar levels of disease activity and HAQ 
(a measure strongly affected by disease activity until late in the disease). In our current 
understanding, ‘tight control’ over (low) disease activity should be maintained over many 
years before benefits in disease progression can manifest themselves in improved patient 
outcome, as expressed by permanent disability, joint replacements etc. 
Not many trials complete such a long and complete follow up of their patients. The BeSt group 
recently confirmed in abstract that the benefits of COBRA (or a combination of high dose MTX 
plus infliximab) on radiographic progression persist up to 5 years25. The FINRACo trial, 
comparing a combination treatment of sulfasalazine, methotrexate, hydroxychloroquine and 
prednisolone with sulfasalazine alone (with or without prednisolone)26 achieved a similar 11-
year follow up. Although their follow up was less complete than ours, they did not encounter 
problems of differential dropout and showed that combination treatment during the first two 
years of disease results in less radiological progression after 11 year follow up compared to 
monotherapy27. 
This study was part of a project to increase uptake of COBRA therapy in rheumatologic 
practice in The Netherlands. We have detected several barriers to implementation on the part 
of the rheumatologist, including the workload, fear of prednisolone and the anticipated 
negative reaction of the patient6. We addressed these by developing information material for 
patients and disseminating scientific evidence that contradicts the physician’s beliefs. The 
current study serves to take away lingering concerns over long-term safety of this strategy, 
and documents that initial COBRA therapy is as safe as other antirheumatic treatment 
modalities in the short and long term, under appropriate rheumatology care. 
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APPENDIX I  Comorbidities 
 
 
Clinical records were searched for the following events: 
 
 
Appendix table 1   List of comobidities searched for in clinical records  
Comorbidities 
Myocardial infarction (MI) 
Cerebral vascular event (CVA) 
Angina pectoris (AP) 
Heart failure 
Peripheral vascular disease 
Osteoporosis (bone mass T score<-2.5)  
Fracture (type) 
Prosthesis (type)  
Synovectomy 
Other joint surgeries  
Avascular bone necrosis  
Diabetes mellitus 
Hypercholesterolemia (treated/untreated)  
Hypertension (treated/untreated)  
Gastrointestinal diseases  
Vitamin D shortage  
Cancer (type)  
Cataract  
Glaucoma  
Infection (with/without hospital admission) 
Tuberculosis 
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APPENDIX II  Drugs used during the 11 year study period   
 
 
METHODS 
The search for drug use in clinical records was done for the years after the initial trial period 
(56 weeks) and was facilitated by the use of original trialdata on drug use after 56 weeks. The 
use of DMARDs and biologicals was registered as yes/no and the use of oral prednisolone 
was registered with dosage and duration of use. In addition to scrutiny of medical records, 
patients were asked to complete a questionnaire on drug use, with specific regard to the use 
of prednisolone and biologicals. 
 
Protocol to calculate mean and cumulative dose of prednisolone 
The calculation of the mean and cumulative dose of prednisolone was protocollized. If data on 
prednisolone dosage in clinical records was incomplete, it was agreed that maximum duration 
of prednisolone at a certain dosage as prescribed by rheumatologists would comprise: 1 week 
for daily dosages >30 mg; 2 weeks for dosages >20 to 30 mg; and 4 weeks for >10 to 20 mg. 
Dosages of 10 mg or less were considered chronic. In cases with gaps in dosage data of one 
year or more, the dose level was interpolated to the next value in case of a lower dose. There 
was no interpolation in cases where the next dose was higher. 
 
RESULTS 
Appendix-table 2 shows that the COBRA group received slightly more prednisolone over the 
10 years after the trial, possible due to the good experience these patients had with 
prednisolone during the trial. COBRA patients also received slightly more methotrexate, while 
SSZ patients received more intra muscular gold, leflunomide and azathiopine. This is most 
likely caused by the trial protocol: COBRA patients who failed to continue on SSZ alone, 
restarted MTX. If SSZ patients failed on SSZ alone, they switched to a non-trial DMARD. 
 
 
 
Appendix table 2   Drugs used during the 11 year study period including trial period 
Drug (after trial period) COBRA (n=74) SSZ (n=72) 
 
Prednisolone * 
Count (%) 
patients 
Count (%) 
patients 
Patients using prednisolone after the trial period 38 (52)   26 (37) 
Mean treatment duration (years) 5.1 (3.9)   4.3 (3.2) 
Mean daily dose (SD) 7.1 (2.2)   6.5 (2.5) 
Cumulative dose (grams) 12.5 (10.2) 10.2 (8.9) 
Mean no of days between end of study and re-start of 
prednisolone (SD) 
3.6 (3.0)   4.5 (3.1) 
Chronic use > 1 year   
 Dose > 7.5 mg/d   8 (26)   5 (24) 
 Dose ≤ 7.5 mg/d 21 (68) 15 (71) 
Chronic use ≤ 1 year   
 Dose > 7.5 mg/d 15 (48) 10 (48) 
 Dose ≤ 7.5 mg/d 9 (29)   5 (24) 
Patients receiving COBRA-like treatment during follow 
up, count (%) 
4 (11)   4 (15) 
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Other DMARDs   
Sulfasalazine 18 (24) 16 (20) 
Methotrexate 57 (77) 47 (66) 
Hydroxychloroquine   9 (12)   9 (13) 
Intra muscular gold 20 (27) 25 (35) 
Leflunomide 6 (8)   8 (11) 
Azathiopine    0 (0) †    6 (9) † 
Cyclosporin 2 (3) 0 (0) 
Auranofin 0 (0) 2 (3) 
D-penicillamine 3 (4) 1 (1) 
Biological   
Infliximab 11 (15) 6 (9) 
Etanercept 6 (8) 5 (7) 
Adalimumab 3 (4) 5 (7) 
Anakinra 1 (1) 0 (0) 
Rituximab 1 (1) 1 (1) 
 
* Nine patients using prednisolone for alternate reasons were excluded 
† Significant difference between treatment groups; p=0.02 
 
Chapter 1.3  
 
58 
REFERENCES 
1.  Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down 
prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid 
arthritis. Lancet 1997: 350 (9074): 309-18. 
2. Landewé RB, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early 
rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002: 46 (2): 
347-56. 
3.  Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic 
outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt 
study): a randomized, controlled trial. Arthritis Rheum 2005: 52 (11): 3381-90. 
4.  Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment 
strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007: 146 (6): 406-15. 
5.  van Tuyl LH, Plass AM, Lems WF et al. Why are Dutch rheumatologists reluctant to use the 
COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007: 66 (7): 974-6. 
6.  van Tuyl LH, Plass AM, Lems WF et al. Discordant perspectives of rheumatologists and patients on 
COBRA combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 2008: 47 (10): 1571-6. 
7.  Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, 
predictors, correlates, and outcomes. J Rheumatol 2007: 34 (4): 696-705. 
8.  Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-
eight-joint counts. Development and validation in a prospective longitudinal study of patients with 
rheumatoid arthritis. Arthritis Rheum 1995: 38 (1): 44-8. 
9.  Siegert CE, Vleming LJ, Vandenbroucke JP, Cats A. Measurement of disability in Dutch rheumatoid 
arthritis patients. Clin Rheumatol 1984: 3 (3): 305-9. 
10. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and 
validity in a patient population. Med Care 1988: 26 (7): 724-35. 
11.  Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in 
rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 
1997: 36 (5): 551-9. 
12. Genant HK, Jergas M, Palermo L et al. Comparison of semiquantitative visual and quantitative 
morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of 
Osteoporotic Fractures Research Group. J Bone Miner Res 1996: 11 (7): 984-96. 
13. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB. Effects of 
hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. 
Lancet 1989: 1 (8646): 1036-8. 
14. van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. 
 J Rheumatol 2000: 27 (1): 261-3. 
15. StatLine database SN. Life Tables 1994 - 2006.  2008. Den Haag/Heerlen.  
16. Da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid 
arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006: 65 (3): 285-93. 
17. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment 
in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008: 47 (1): 
59-64. 
18. Korthals-de Bos I, van Tulder M, Boers M et al. Indirect and total costs of early rheumatoid arthritis: 
a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine 
with sulfasalazine alone. J Rheumatol 2004: 31 (9): 1709-16. 
19. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility 
of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down 
prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. 
Combinatietherapie Bij Reumatoide Artritis. Br J Rheumatol 1998: 37 (10): 1102-9. 
20. Kroot EJ, van Leeuwen MA, van Rijswijk MH et al. No increased mortality in patients with 
rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000: 59 (12): 
954-8. 
21. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J 
Med 1953: 249 (14): 553-6. 
22. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 
2007: 21 (5): 871-83. 
23. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994: 37 
(4): 481-94. 
24. Boers M. Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. J Rheumatol 2007: 
34(4): 661-3. 
11-year follow up of the COBRA trial  
59 
25. Klarenbeek N, Guler-Yuksel M, van der Kooij S et al. Clinical and Radiological Outcomes in Recent 
Onset Rheumatoid Arthritis after 5 Years of DAS-steered Treatment in the BeSt-Study. Arthritis 
Rheum 2008:58[9 (suppl)], S899-S900. 
26. Möttönen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-
drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999: 
353 (9164): 1568-73. 
27. Rantalaiho V, Laasonen L, Kautiainen H et al. Window of opportunity in early rheumatoid arthritis. 
Combination therapy with FIN-RACo strategy during first 2 years translates into less joint erosions in 
11-year radiographs. Arthritis Rheum 2008: 58[9 (suppl)], S918. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
Chapter 1.4 
 
 
Baseline RANKL:OPG ratio and markers of bone and 
cartilage degradation predict annual radiological 
progression over 11 years in rheumatoid arthritis 
 
 
 
Lilian HD van Tuyl 1 
Alexandre E Voskuyl 1 
Maarten Boers 1,2 
Piet P Geusens 3,4 
Robert BM Landewé 3 
Ben AC Dijkmans 1 
Willem F Lems 1 
 
 
1 Department of Rheumatology 
2 Departement of Epidemiology & Biostatistics 
 VU University Medical Center, Amsterdam, The Netherlands 
3 Department of Internal Medicine / Rheumatology,  
 Maastricht University Medical Center, Maastricht, The Netherlands 
4 Biomedical Research Institute, University Hasselt, Belgium 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted 
Chapter 1.4  
62 
ABSTRACT 
 
 
OBJECTIVE 
Traditional predictors of radiological progression in rheumatoid arthritis (RA) are mostly 
markers of inflammation. We investigated to what extent baseline measurements of the ratio 
of receptor activator of nuclear factor κB ligand (RANKL) / osteoprotegerin (OPG) and C-
terminal cross linking of type-I and type-II collagen (CTX I and CTX-II) in addition to traditional 
markers of disease severity, could predict annual radiological progression.  
 
METHODS 
A cohort of 155 early, active, untreated RA patients that participated in the COBRA trial was 
followed for 11 years. Urine was sampled at baseline and after 3 months from start of 
treatment and analyzed for CTX-I and CTX-II. Baseline serum samples were analyzed for 
RANKL and OPG. Available traditional markers of disease severity included baseline 
measurements of erythrocyte sedimentation rate, rheumatoid factor and baseline radiological 
damage. A digital database of frequent radiographs was available, scored according to the 
Sharp/van der Heijde method. Individual annual progression rates were calculated and used 
as outcome variable. Multiple linear regression analyses identified the strongest predictors of 
annual radiological progression.  
 
RESULTS 
In multivariable analyses the RANKL:OPG ratio and CTX-I or CTX-II proved to be 
independent predictors of annual radiological progression over 11 years. The prediction of 
annual radiological progression was strongest when the RANKL:OPG ratio and CTX-I or CTX-
II were evaluated in the same model (36 to 39% explained variance). Adding the effect of 
treatment at 3 months to the baseline models improved the predictive ability of the models up 
to 44 to 46%. 
 
CONCLUSION 
Unfavourable baseline levels of the RANKL:OPG ratio as well as CTX-I (markers of bone 
resorption) and CTX-II (a marker of predominantly cartilage degradation) in patients with 
early, active, untreated RA are strong independent predictors of rapid and persistent damage 
progression over 11 years follow up. Early improvement in bone markers on treatment 
predicts better outcome. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic auto-immune disease characterised by inflammation of 
primarily the joints, followed by cartilage degradation and subchondral bone erosion1. 
Cartilage and bone damage can be visualised on radiographs and quantified using several 
different scoring techniques resulting in a total damage score2-4. The rate of radiological 
progression is different for every patient and substantial research has been done to identify 
markers that can best predict future radiological progression. Traditional predictors of future 
joint damage include measures of disease activity, such as the erythrocyte sedimentation rate 
(ESR), the disease activity scale (DAS), serum C-reactive protein (CRP) levels, rheumatoid 
factor (RF) positivity, anti-cyclic citrullinated peptide (anti-CCP) and baseline radiological 
damage5-7. It is generally believed that inflammation is the cause of future radiological 
damage, but there are indications that joint inflammation and destruction may be partly 
independent, as destruction may continue despite effective suppression of inflammation or 
stop during treatment in the face of persistent inflammation8,9. In this context, markers of bone 
and cartilage destruction are of high interest. 
 
The COBRA study was a randomized trial that compared the combination of sulfasalazine 
(SSZ), methotrexate (MTX), and prednisolone with sulfasalazine alone10. Combination 
therapy proved to be more effective in suppressing the inflammation process than SSZ 
monotherapy. This rapid suppression of inflammation resulted in a sustained reduction of the 
progression of radiological joint damage sustained over 5 years follow up, despite similar 
treatment and disease activity in the follow up period11.  
 
Over the last years, a series of studies in the COBRA follow up dataset have increased our 
understanding of the importance of bone and cartilage markers. We showed that high 
baseline levels of urinary excretion of C-terminal cross linking of type-I and type-II collagen 
(CTX-I and CTX-II) and the CTX-II response after 3 months of therapy independently 
predicted an increased risk of radiological progression over 4 years, especially in patients 
without radiological damage at baseline12,13. Further we showed that a direct longitudinal 
relationship exists between clinically perceptible signs of arthritis and degradation of CTX-I 
and especially CTX-II14. These and other studies15-17 suggest that in RA urinary excretion of 
CTX-II most likely represents joint cartilage and bone loss, whereas excretion of CTX-I, less 
prominently associated with clinical signs of arthritis, most likely represents both generalised 
and localised bone loss.  
 
Another marker for bone loss or more specifically for osteoclast activation is the ratio between 
receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) in serum18. 
RANKL induces osteoclastic bone destruction, and OPG is its decoy receptor that prevents 
bone destruction by preventing the binding of RANKL with its receptor RANK. Because bone 
resorption is regulated by the relative expression and production of RANKL and OPG levels, 
the ratio of these (RANKL:OPG) is often used as a marker of osteoclast activation. In the final 
study of the COBRA dataset we demonstrated that low baseline OPG:RANKL ratios also 
predicted 5-year radiological progression19. 
 
Recently, we completed the 11 year follow up of the COBRA trial, including long term 
outcome of radiological progression in patients with 11 years rheumatoid arthritis20. These 
data provide a unique opportunity to confirm the predictive ability of bone markers CTX-I, 
CTX-II and the RANKL:OPG ratio as well as traditional disease activity related markers for 
annual radiological progression over 11 years follow up. 
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METHODS 
The COBRA cohort 
The multicenter, randomized, double blind controlled COBRA trial included 155 patients with 
early, active rheumatoid arthritis, in which COBRA combination therapy was compared with 
SSZ monotherapy. Details of the initial trial, the 5-year follow up and the 11 year follow up 
have been reported previously10,11;20. COBRA combination therapy is a step-down treatment 
strategy comprising sulfasalazine (2 g/day), methotrexate (7.5 mg/week) and an oral pulse of 
prednisolone, starting with 60 mg in the first week and tapered to 7.5 mg in the 7th week. At 28 
weeks, prednisolone is tapered and withdrawn and after 40 weeks, MTX is withdrawn. 
Patients in the SSZ group received SSZ (2 g/day) and placebo MTX and prednisolone. 
Medication was protocollized up to 56 weeks, after this period treatment decisions were made 
at the discretion of the treating rheumatologists.  
Measurements of traditional predictors of radiological progression measured during the trial 
period that were available for the current study included: ESR, rheumatoid factor positivity, 
baseline radiological damage, and the health assessment questionnaire (HAQ). 
All participating patients gave their written informed consent to join in the 11-year follow up 
study and the proposal was approved by the medical ethical committee of the VU University 
Medical Center.  
 
Radiology 
A digital, radiological database of the COBRA cohort was available, comprising all available 
radiographs of every patient since the start of the COBRA trial. This database contained 
radiographs of hands and feet, scored by two independent assessors according to the 
Sharp/van der Heijde (SvH) method4;21. Assessors were blinded for group allocation but 
aware of time sequence. Scores can be stable, increase or decrease. The mean of the 2 
observers’ scores were used to calculate the total SvH score at every time point. 
Radiological progression for each patient was expressed as the annual progression rate 
(expressed as total SvH score per year). This annual progression rate was calculated for each 
patient individually, by linear regression analysis on every available radiograph of that patient 
with time as the independent variable, thus providing the most accurate estimate for the 
regression coefficient. A mean of 8 (range 2 to 11) radiographs were available for each 
patient to calculate the annual radiological progression rate. 
 
Bone markers 
Urine samples (second morning void, nonfasting) were obtained at baseline and 3 months 
after start of the trial and kept frozen at -20°C.  Urinary excretion of CTX-I and CTX-II were 
measured at baseline and 3 months after start of the trial, by the CrossLaps enzyme-linked 
immunosorbent assay (ELISA) (Osteometer Biotech, Herlev, Denmark). Details of this essay 
are described elsewhere12-14. 
Serum was obtained at baseline and kept frozen at -20°C. Baseline levels of RANKL and 
OPG in serum were measured by a capture enzyme-linked immunosorbent assay, with 2 
antibodies detecting different epitopes12. RANKL was measured by personnel at Amgen 
(Thousand Oaks, CA), using 2 in-house-produced antibodies and OPG was measured with a 
commercially available kit (Biomedica Medizinprodukte, Vienna, Austria). The levels of 
RANKL and OPG were expressed as a ratio RANKL:OPG, reflecting bone destruction if >1 
and bone formation/preservation when <1. 
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Analysis 
The distribution of the variables CTX-I, CTX-II, RANKL:OPG in relation to annual radiological 
progression all improved after a log-transformation (natural logarithm) of the predictors as well 
as the outcome measure. All the results of these variables presented in this manuscript relate 
to the log (ln) transformed data. Scatterplots and Pearson’s correlation coefficient of 0.65 
(p<0.001) confirmed the high correlation between CTX-I and CTX-II reported earlier13. For this 
reason and the possibility that these markers might measure similar processes, they were 
analyzed in separate models. The correlations between CTX-I or CTX-II and RANKL:OPG 
were weak and it was thus decided that these markers can be analyzed in the same model.  
Radiological progression was defined as the mean yearly progression rate, calculated through 
individual linear regression over the available observations of a patient. Not all patients had 
CTX-I, CTX-II and RANKL:OPG measurements available. For that reason, the CTX-I and 
CTX-II models were investigated both with and without RANKL:OPG. Furthermore, 
RANKL:OPG was evaluated with and without CTX-I or CTX-II. Table 1 gives an overview of 
the patients and available measurements for each dataset.  
 
 
Table 1   Characteristics of the study participants 
 
CTX-I 
dataset 
CTX-II 
dataset 
RANKL:OPG 
dataset 
CTX-I + 
RANKL:OPG 
dataset 
CTX-II + 
RANKL:OPG 
dataset 
Baseline characteristics (n=97) (n=104) (n=100) (n=67) (n=73) 
Age, years 50 (12) 50 (12) 49 (13) 49 (13) 49 (13) 
% female 59 59 59 55 56 
Disease duration (mo) 6 (5) 5 (5) 5 (5) 5 (5) 5 (5) 
ESR 52 (33) 52 (32) 52 (31) 49 (30) 49 (30) 
HAQ score (range 0-3) 1.4 (0.7) 1.4 (0.7) 1.5 (0.7) 1.4 (0.7) 1.5 (0.7) 
CTX-I (ln) 5.2 (0.6) n/a n/a 5.2 (0.6) n/a 
CTX-I 209 (109) n/a n/a 146 (102) n/a 
CTX-II (ln) n/a 5.8 (0.8) n/a n/a 5.8 (0.8) 
CTX-II n/a 462 (419) n/a n/a 471 (454) 
RANKL:OPG ratio (ln) n/a n/a -0.3 (1.8) -0.2 (1.8) -0.3 (1.9) 
RANKL:OPG ratio  n/a n/a 3.5 (9.3) 4.2 (11.2) 3.9 (10.8) 
% rheumatoid factor positive 74 73 70 67 66 
% with baseline radiologic 
damage  
77 77 76 75 74 
Baseline radiologic damage  
(mean SvH (SD) median) 
9 (13) 3 9 (13) 3 8 (11) 3 8 (12) 3 8 (11) 3 
Annual radiological 
progression (ln) 
(mean SvH (SD) median) 
1.5 (0.9) 1.5 1.5 (0.9) 1.5 1.5 (1.0) 1.5 1.4 (0.9) 1.4 1.4 (0.9) 1.4 
Annual radiological 
progression  
(mean SvH (SD) median) 
5.4 (0.6) 3.5 5.4(0.6) 3.5 5.7 (0.7) 3.5 4.8 (0.6) 3.1 5.0 (0.7) 3.0 
Characteristics at 3 months follow up 
ESR 3 months 20 (18) 21 (20) 22 (22) 19 (17) 19 (17) 
CTX-I 3 months (ln) 4.7 (0.8) n/a n/a 4.7 (0.8) n/a 
CTX-I 3 months 148 (104) n/a n/a 146 (102) n/a 
CTX-II 3 months (ln) n/a 5.3 (0.8) n/a n/a 5.4 (0.8) 
CTX-II 3 months n/a 292 (252) n/a n/a 278 (213) 
CTX-I and CTX-II are expressed as µgram/mmol creatinine; these and the RANKL:OPG ratio and annual radiological 
progression are presented as true values as well as log (ln) transformed values. 
Mean (SD) unless stated otherwise 
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To investigate the strength of the relationship between all biologically plausible predictors and 
annual radiological progression individually, we first studied all variables separately using 
univariate linear regression. Subsequently, in a backwards selection procedure, one variable 
at a time is taken out based on its lack of statistical significance, with p>0.10 as a cut-off for 
exclusion. The full model contained the variables: baseline damage (dichotomous, SvH≤0.5 or 
>0.5), rheumatoid factor positivity, baseline ESR, 3 month change from baseline ESR, 
baseline CTX-I, 3 months change from baseline CTX-I, baseline CTX-II, 3 months change 
from baseline CTX-II, RANKL:OPG, HAQ at baseline and sex. Backwards regression analysis 
was done in two steps: first including only baseline variables and secondly including baseline 
as well as available 3 months follow up measurements. 
 
RESULTS 
Univariate linear regression analysis showed that all three bone markers were significantly 
related to annual radiological progression (depending on the dataset used). RANKL:OPG is 
the strongest univariate predictor followed by CTX-II at 3 months and rheumatoid factor 
(Table 2). Due to the poor predictive ability of HAQ and sex in our datasets these variables 
were excluded from the multivariate analysis. 
 
 
Table 2   Univariate relationship between measures of disease activity, bone markers at 
baseline or during treatment and annual radiographic progression, expressed as percentage 
explained variance (R2) of the model, in different subsets of the database. 
Variable                          Univariate R
2 
     (range in the 5 subsets of the database) 
HAQ  0 – 0.9 
SEX  0.3 – 4 
Baseline damage  2 – 6 § 
CTX-I  4 – 10 ‡ 
CTX-I op T3  10 – 11 ‡ 
CTX-II  10 – 14 ‡ 
ESR op T3  8 – 16 § 
ESR  11 – 16 § 
RF  10 – 19 § 
CTX-II op T3  17 – 20 § 
RANKL:OPG  19 – 21 § 
CTX-I, CTX-II, RANKL:OPG and the outcome variable annual progression rate are all log transformed 
R2 = percentage explained variance by the variables in the statistical model 
‡ p<0.01; § p<0.001 
 
 
In multivariate analysis in both the CTX-I and CTX-II dataset, radiological progression was 
explained by a high baseline ESR and a positive test for RF (Table 3). These models 
explained 18 and 22% of the variation in annual radiological progression respectively.  
The dataset optimized for bone marker RANKL:OPG, without CTX-I or CTX-II (n=100), 
provides a model explaining 32% of annual radiological progression and is determined by a 
high baseline ESR, a positive test for RF and a high RANKL:OPG ratio. 
 
The models combining CTX-I or CTX-II with RANKL:OPG predict 36 to 39% of variance and 
include RANKL:OPG ratio, CTX-I or CTX-II, ESR and RF in case of the CTX-I dataset and 
baseline damage in case of the CTX-II dataset.  
Including follow up measurements of CTX-I, CTX-II and ESR at 3 months improves the 
predictive ability of the different models. With 44 to 46% explained variance, the models 
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containing both RANKL:OPG and CTX-I or CTX-II predict radiological progression best. In the 
CTX-I dataset, annual radiological progression is best predicted by the presence of baseline 
damage, a high ESR 3 months after start of treatment, a positive test for RF at baseline, a 
high CTX-I at baseline and a high RANKL:OPG ratio at baseline. For the CTX-II dataset, 
annual radiological progression is best determined by the presence of radiological damage at 
baseline, a high ESR 3 months after start of treatment, a high CTX-II 3 months after start of 
treatment and a high RANKL:OPG ratio. 
 
These analyses suggest that especially a high baseline RANKL:OPG ratio in serum strongly 
predicts a high annual progression rate. Figure 1 illustrates the model of the dataset 
containing CTX-II, the RANKL:OPG ratio and 3 month follow up measures, with the predicted 
radiological damage of patients with an unfavourable level of either RANKL:OPG, ESR, CTX-
II at 3 months or baseline damage (R2=46%). 
 
 
Table 3   Beta coefficients of the best models based on backwards regression analysis 
 CTX-I 
(n=97) 
CTX-II 
(n=104) 
 
RANKL:OPG 
(n=100) 
CTX-I + 
RANKL:OPG 
(n=67) 
CTX-II + 
RANKL:OPG 
(n=73) 
Baseline measurements only 
Baseline damage 
(SvH>0.5) - - - - 0.35
 
* 
ESR 0.01 ‡ 0.01 § 0.01 ‡ 0.01 † 0.01* 
RF 0.55 ‡ 0.55 ‡ 0.51 † 0.46 † - 
CTX-I - n/a n/a 0.37 † n/a 
CTX-II n/a - n/a n/a 0.24 † 
RANKL:OPG n/a n/a 0.13 † 0.12 † 0.17 ‡ 
R2 18% 22% 32% 39% 36% 
Baseline and 3 month follow up measurements 
Baseline damage 
(SvH>0.5) 
- - - 0.33 * 0.33 * 
ESR - 0.01 ‡ 0.01 ‡ - - 
ESR_T3 0.01 † - - 0.01 ‡ 0.01† 
RF 0.52 ‡ 0.48 ‡ 0.51 † 0.40 * - 
CTX-I - n/a n/a 0.34 † n/a 
CTX-I T3 0.26 † n/a n/a - n/a 
CTX-II n/a - n/a n/a - 
CTX-II T3 n/a 0.34 ‡ n/a n/a 0.40 ‡ 
RANKL:OPG n/a n/a 0.13 † 0.15 † 0.20 § 
R2 23% 29% 32% 44% 46% 
n/a: not available in the dataset used for this analysis 
Five different datasets were available and in each dataset the ‘best’ model was sought through a backwards regression 
analysis including all variables with a biologically plausible relationship with the outcome variable annual radiological 
progression.  
* p<0.1; † p<0.05; ‡ p<0.01; § p<0.001 
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Figure 1   Effect of modelling prognostic factors on radiological progression over 11 years in patients 
with early RA. The grey line shows progression in a patient with all factors at their median. The other lines 
show the effect on progression of increasing one single factor to the value of the 90th percentile.  
For example, the highest dotted line shows the radiological progression when CTX-II 3 months and ESR 3 
months are at their median, baseline damage is absent, but the RANKL:OPG ratio is at its 90th percentile. 
The vertical box on the right represents the distribution from the 25th to 75th percentile of radiological 
damage 11 years after inclusion in the COBRA trial, if every patient would have started with zero baseline 
damage; median radiological damage at 11 years as thick bar. 
Regression equation: ln (annual radiological progression + 1) = 
0.4 * lnCTX-II 3 months + 0.01 * ESR 3 months + 0.2 * lnRANKL:OPG + 0.33 * baseline damage (no/yes) 
The model is based on the dataset containing CTX-II, RANKL:OPG and 3 month follow up measures, 
explaining 46% of variance in radiological progression. Variables (median, 90th percentile): lnCTX-II 3 
months (3.07, 6.54) ; ESR (16, 46), lnRANKL:OPG (-0.249, 1.77), baseline damage (no 0, yes 1) 
 
 
DISCUSSION 
This study confirms the importance of RANKL:OPG and CTX-I and CTX-II as predictors of 
long term radiological progression. In addition to earlier work, this study combined 
measurements of CTX-I or CTX-II with RANKL:OPG in one prediction model and found an 
even stronger relationship with annual radiological damage than when these markers are 
modeled separately. As shown before, these bone markers measured at baseline are 
stronger predictors of progression of radiological damage than traditional predictors such as 
baseline measurements of ESR, radiological damage and RF.  
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The baseline RANKL:OPG ratio as well as CTX-I and CTX-II were measured at an early and 
active stage of the disease, in mostly DMARD naïve patients. The relationship between these 
baseline markers and long term radiological progression suggests that the course of 
radiological progression is presumably already determined at a very early stage of the 
disease. However, the predictive ability of the 3 months change from baseline in CTX-I and 
CTX-II levels shows that effective treatment can alter this course. The identification of patients 
with high baseline levels of CTX-I, CTX-II and especially a high RANKL:OPG ratio can help to 
estimate the severity of the disease and point to indication for aggressive treatment. More 
research is needed to investigate the effect of treatment on the RANKL:OPG ratio. 
Looking at the explained variance from models including both CTX-I or CTX-II and 
RANKL:OPG compared to the separate models, it shows that the combination of markers 
CTX-I or CTX-II with RANKL:OPG compliment each other. This supports the assumption that 
those measurements reflect different disease mechanisms, with CTX-I reflecting generalized 
boneloss, CTX-II predominantly reflecting cartilage degradation and a high RANKL:OPG ratio 
reflecting inflammation driven local bone loss around the joints. 
 
The strong predictive value of RANKL:OPG on annual radiological progression is supported 
by several different findings; RANKL inhibition is correlated with a marked suppression of 
bone erosion in several animal studies22,23. Furthermore, the RANKL:OPG ratio has been 
shown to play a central role in bone resorption in postmenopausal osteoporotic women as 
well as during inflammation24,25. Crotti et al showed that synovial RANKL expression is 
increased in RA patients with active disease compared to patients with quiescent disease26. 
The production of inflammatory cytokines in inflamed joints is likely to increase RANK and 
RANKL presentation, thus promoting osteoclast-development and subsequent local bone 
destruction27. The increased levels of RANKL in inflamed joints lead to a high RANKL:OPG 
ratio reflecting bone destruction, which is predictive of increased radiological progression19. 
This fundamental research, in combination with our own observations point to the crucial role 
of RANKL:OPG in the development of bone destruction and erosion in RA. In this context, it 
would be of great interest to study whether RANKL inhibition would prevent any new erosion 
to occur in human RA if given early in the disease, before erosions have occurred. In fact, 
Cohen et al have recently shown that denosumab, a human monoclonal IgG2 antibody that 
binds RANKL and thus inhibits its activity, delayed structural damage, improved bone mineral 
density and suppressed bone turnover in established RA patients28. 
 
Young-Min et al studied the predictive ability of several biomarkers among which CTX-II, and 
compared their performance to traditional markers of radiological progression17. This group 
concluded that CTX-II predicted radiological progression better than traditional markers, 
including CRP. However, a letter send in by Tchetverikov et al reminded the readers that the 
currently most important marker of radiological progression is anti-cyclic citrillunated peptide 
(anti-CCP) and was not included in the comparison, a limitation we share with Young-Min and 
colleagues29. Syversen and colleagues showed that anti-CCP, ESR, RF and the female 
gender are strong predictors of 10-year radiographic progression, with anti-CCP as the 
strongest contributor to the prediction model30. However, this group recently showed that 
levels of RANKL and OPG measured in serum did not contribute to the predictive ability of 
current predictors as anti-CCP, baseline damage and signs of inflammation31. A large 
difference between the studies reported by Syversen et al and our study is that they studied a 
population with mild RA, while we studied patients with early aggressive RA. Further, we used 
the RANKL:OPG, while Syversen et al used the separate components. Nevertheless, it is a 
shortcoming of our study that anti-CCP was not measured in this cohort since anti-CCP is one 
of the strongest predictors of radiological damage5,6;32,33. The predictive ability of CTX-I, CTX-
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II and the RANKL:OPG ratio in a multivariate model including anti-CCP should be further 
investigated. 
Because the COBRA trial was not designed to investigate bone markers as a predictor in RA 
outcome, these measurements were done on residual sera that were available approximately 
7 years after the trial period. Unfortunately, not every patient had enough urine or serum 
available to do the CTX measurements, and even less patients had enough material left to do 
additional RANKL and OPG measurements. However, sample collection, storage and 
measurements were all done in a blinded fashion, without knowledge of disease activity or 
long term radiological outcome, making selection-bias unlikely.  
The OMERACT soluble biomarker group has formulated 12 validation criteria for soluble 
biomarkers to be regarded as valid with respect to reflecting structural damage endpoints in 
RA34-36. The current research strengthens the case for CTX-I, CTX-II and RANKL:OPG as 
valid biomarkers based on their independent association with change in structural damage 
endpoints in this clinically well defined prospective cohort with 11 year follow up. 
 
In summary, measures of osteoclast activity reflected in the RANKL:OPG ratio and markers of 
bone and cartilage degradation CTX-I and CTX-II in patients with early, aggressive, untreated 
RA continue to predict annual radiological progression over 11 years follow up. 
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ABSTRACT 
 
 
OBJECTIVE 
COBRA combination therapy is well-known and has uncontested efficacy in the treatment of 
rheumatoid arthritis. However, it is infrequently applied in Dutch clinical practice.  
Based on qualitative research on opinions of physicians and patients towards COBRA 
therapy, the current study describes the development and pilot testing of an implementation 
package to facilitate prescription and use of COBRA therapy in early rheumatoid arthritis. 
 
METHODS  
The implementation package was developed to tackle specific barriers towards prescription of 
COBRA therapy and comprised informational handouts (an information booklet and leaflet for 
patients), pre-printed prescription orders and background information on COBRA therapy for 
the rheumatologists. Twenty-two rheumatologists agreed to participate, including the arthritis 
nurse where available. Rheumatologists, nurses and patients were asked to record their 
experience. Furthermore, all Dutch arthritis nurses were invited to an educational session on 
COBRA therapy. 
 
RESULTS 
Sixteen rheumatologists accompanied by 10 arthritis nurses used the material to prescribe 
COBRA therapy to a total of 27 patients. Rheumatologists and arthritis nurses both gave high 
marks to the supplied materials. 88% of rheumatologists reported that the material speeded 
up the prescription process and 65% indicated they would prescribe COBRA therapy more 
frequently if these materials were available routinely. Patients expressed great satisfaction 
with the information handouts, rating it 2.8 (SD:0.5) on a scale of -3 (very negative) to +3 
(very positive). Most patients (89%) planned to keep the information booklet as a reference 
and 70% used it as a tool to remember the correct intake of medication. The attitude and 
perceived capability of arthritis nurses towards the guidance of RA patients on COBRA 
therapy was improved through a brief educational intervention. 
 
CONCLUSION  
Rheumatologists, patients and arthritis nurses all highly appreciated the implementation 
package and indicated that its availability would increase uptake of COBRA therapy. 
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INTRODUCTION 
Over the past few decades, many clinical trials in rheumatology have shown the effectiveness 
and safety of different combinations of disease modifying antirheumatic drugs (DMARDs) for 
the treatment of rheumatoid arthritis (RA)1-6.  
A well-known and well-documented combination strategy is the COBRA therapy, comprising 
methotrexate, sulfasalazine and step-down high dose prednisolone. This therapy proved to be 
more effective than SSZ monotherapy in a randomised controlled trial1, and the delay of 
radiographic damage to the joints was still detectable after 5 years follow up7. It is recently 
shown that COBRA therapy is as effective as initial combination therapy of high-dose MTX 
with infliximab8. Furthermore, COBRA therapy is a combination of inexpensive, generic drugs 
and is therefore likely to be highly cost-effective compared to the newer biologic treatments; 
COBRA therapy already proved to be equally cost-effective compared to SSZ 
monotherapy9,10. Although all evidence is in favour of COBRA therapy, prescription of this 
combination therapy for the treatment of early RA is not common. This is remarkable since 
there is a large body of evidence for the superiority of combination therapy over 
monotherapies1-6;8. It has been shown that a multifaceted approach is needed to implement 
research evidence that does not find its way into clinical practice11,12. 
 
To investigate and improve the uptake of COBRA combination therapy in clinical practice, the 
COBRA implementation study started in 2005, comprising three main phases: phase1: 
identification of facilitators and barriers among Dutch rheumatologists towards prescribing 
COBRA therapy, phase 2: follow up of the original trial cohort to investigate long term 
effectiveness and safety, and phase 3: implementation of COBRA therapy in clinical practice 
with material facilitating use, including an information-booklet and a website13. The 
identification of facilitators and barriers started with a brief inquiry into the uptake of COBRA 
therapy in daily practice14. This study showed that rheumatologists rarely used COBRA 
therapy outside trials. It also showed the contradictory perspective of rheumatologists towards 
COBRA therapy: although they regarded COBRA therapy as effective and safe, 
rheumatologists indicated it was unlikely that they would treat a patient with COBRA therapy 
in the near future. After this brief inquiry, a large qualitative study was conducted to 
investigate all perspectives and perceived barriers towards the use of COBRA therapy. The 
opinion of patients towards intensive combination therapy with SSZ, MTX and prednisolone 
was also studied15. Results again showed rheumatologists regarded COBRA therapy as 
effective, but were highly concerned about their patients’ possible negative reaction towards 
the large amount of pills to be prescribed. In addition, rheumatologists perceived lack of time 
explaining and prescribing COBRA therapy and felt uncomfortable prescribing high doses of 
prednisolone. Patients were positive about an aggressive combination therapy such as 
COBRA, and they had no qualms taking many pills if this could improve their prognosis. 
Patients associated prednisolone with negative side-effects, but were also aware of the 
benefits and the need of prednisolone in rough times. 
 
With this knowledge on rheumatologists’ and patients’ opinion, an implementation plan was 
developed and pilot-tested to facilitate prescription and use of COBRA therapy in early 
rheumatoid arthritis by the rheumatologist, the patient and the arthritis nurse. 
 
METHODS  
Study design 
This pilot study was conducted from March to October 2007; feasibility and acceptability of 
components of the implementation plan used by rheumatologists, arthritis nurses and patients 
were assessed cross-sectional through structured questionnaires. Furthermore, the effect of 
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an educational intervention on arthritis nurses’ attitude and perceived capability towards the 
use of COBRA therapy in their clinical practice was investigated. 
 
Subjects 
Rheumatologists were selected based on their attitude towards COBRA therapy, as 
measured during the questionnaire phase of this study, reported in detail elsewhere14. To 
assure that rheumatologists were willing to prescribe the therapy to patients that were eligible 
for this study, we invited thirty rheumatologists with a positive attitude towards COBRA 
therapy to participate in the pilot implementation study. Twenty-two reumatologists from 
fourteen different centres in The Netherlands accepted our invitation. These 22 
rheumatologists were asked to involve the arthritis nurse (if employed in the medical center). 
In order to have diversity, all rheumatologists were asked to prescribe COBRA therapy to a 
maximum of 3 patients, using the provided materials. Inclusion criteria were not strict: all 
patients could be included if they were diagnosed with rheumatoid arthritis 2 years or less 
prior to inclusion unless they had been treated with COBRA therapy before.  
Furthermore, all Dutch arthritis nurses (n≈100) were invited to an education session on 
COBRA therapy later that year. 
 
Intervention and provided materials 
Taking into account the perceived barriers of rheumatologists, an implementation package 
was designed to facilitate prescription of COBRA therapy for rheumatologists (See Table 1).  
The perceived workload was tackled by providing the rheumatologists with four tools:  
1): a specific COBRA therapy information booklet (see Figure 1) including a leaflet with a 
summary of the first consult in which the therapy is explained. The booklet (20 pages) was 
developed based on available booklets on the separate drugs SSZ, MTX and prednisolone. 
Specific attention was paid to the additional value of combined treatment, the visual 
representation of intake of drugs by tables and figures, and the recognition of the patients’ 
feelings by an interview with a fictional RA patient coping with the diagnosis RA. Many of 
these ideas were provided or confirmed by rheumatologists and patients during the focus 
group discussions preceding this implementation pilot study15. 2): pre-printed prescriptions on 
a sticker patch for the first 3 months of therapy; 3): an example consult, giving the 
rheumatologist an idea on how to motivate and inform their patient (this scenario was tested 
during focus group discussions with patients and evaluated as very clear and motivating to 
early RA patients15; 4): all patients were referred to the arthritis nurse. This nurse explained 
the therapy more extensively, answered questions and called the patient once a week during 
the first month of therapy to answer any additional questions. Furthermore, the participating 
rheumatologists and arthritis nurses were informed of the results about the patients’ opinion 
from our qualitative study. Scientific articles on this and related subjects were provided.  
Later that year, all Dutch arthritis nurses were invited to an educational afternoon on COBRA 
combination therapy, where they learned more about the therapy during a two hour interactive 
session.  
 
Measurements 
Three similar questionnaires were developed to evaluate the information material and 
prescription process from the rheumatologist-, arthritis nurse- and patient- point of view.  
The information leaflet and the information booklet were evaluated through questions using 
semantic differentials (annoying vs pleasing; patronizing vs considerate; complex vs simple; 
important vs meaningless; clear vs unclear; bad vs good; a lot vs a little; confusing vs 
enlightening; clear vs unreadable; inviting vs boring; well structured vs messy; beautiful vs 
ugly; realistic vs unrealistic; useful vs unnecessary; boring vs captivating) on a 7-point Likert 
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scale. Thus, a score of -3 indicates a most negative attitude towards the probed question and 
a score of +3 indicates a most positive attitude towards the probed question. Every aspect of 
the material was evaluated by 5 different semantic differentials, thus giving a complete 
evaluation of that aspect. An open ended question asked participants for ‘other remarks’ 
about the material or therapy. The rheumatologists’ questionnaire ended with multiple choice 
questions (yes/no/neutral) about the usefulness of the provided material in the implementation 
package and the intention of rheumatologists to prescribe COBRA therapy more often if the 
implementation material would be available to them. It also queried whether the consult went 
faster using the material than without it. The patient questionnaire was similar to the 
rheumatologist questionnaire with addition of questions about the use of the information 
leaflet to inform other persons about their disease; the use of the information booklet as a tool 
to remember the correct intake of all drugs; and evaluation of the role of the arthritis nurse. 
Arthritis nurses were asked, besides the general questions on the material and process, if 
they felt that Dutch arthritis nurses had sufficient knowledge on COBRA therapy and if they 
felt it useful to call the patient every week during the first month of the therapy. 
Questionnaires were provided by the research team with a post-paid return envelope. 
Rheumatologists and arthritis nurses were asked to fill out the questionnaire directly after the 
consultation with the patient. The patient was asked to fill out the questionnaire two weeks 
after the start with COBRA therapy.  
Eighty-seven arthritis nurses attended the educational afternoon on COBRA therapy. Before 
the start of the session, all arthritis nurses completed a short questionnaire (pre-test) on the 
basis of the social psychological theory of planned behaviour, which explains behaviour 
through behavioural intention, attitude, social influence and perceived control16. 
 
 
Table 1   Barriers towards the use of COBRA therapy in clinical practice 
Rheumatologist barrier * Implementation package 
Workload 1. Specialised COBRA therapy information booklet  
2. Pre-printed prescriptions 
3. Example consult 
4. Refer to arthritis nurse 
Anticipated negative reaction of 
patient 
Dissemination of focus group results among 
rheumatologists and arthritis nurses: patients are 
positive about intensive combination therapy such as 
COBRA. Taking many pills is not regarded problem, if 
this improves long term prognosis. A decrease in the 
amount of pills over time is highly appreciated. 
Fear of prednisolone Dissemination of scientific articles of the COBRA and 
BeSt trial. 
Patient barrier  
Comfort 1. Provide information booklet for reference and leaflet 
for summary 
2. Offer additional support from an arthritis nurse  
Negative perception of 
prednisolone  
Emphasise the temporary nature (using visual aids in 
the booklet and leaflet) 
Amount of pills Emphasise the temporary nature (using visual aids in 
the booklet and leaflet) 
Arthritis nurse barrier  
Knowledge on COBRA therapy 1. Provide information material about COBRA therapy 
2. Provide education 
* Barrier as assessed in focus group discussions and in-depth interviews 
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This questionnaire was originally designed in the former phase of our study (phase 1) 
according to the protocol of Aizen14;16. Questions were based on a 7-point Likert scale, in 
which value -3 was most negative, value 3 was most positive and value 0 was neutral. This 
questionnaire measured the current knowledge, experience and attitude of arthritis nurses 
towards COBRA therapy. The final question prompted if arthritis nurses felt capable of guiding 
a patient with early rheumatoid arthritis that started treatment with COBRA therapy. After a 2 
hour interactive lecture on modern treatment of RA and the use of COBRA therapy by WL 
and LvT, the 62 remaining arthritis nurses completed the same questionnaire (post-test).  
 
Data analysis 
Negatively worded items on questionnaires were recoded for analysis. Results were 
statistically analysed by parametrical (t) and nonparametrical (Mann-Whitney) tests where 
applicable.  
The questionnaires that were developed to evaluate the information material and prescription 
process used multiple semantic differentials (items) to answer a question. Factor analysis was 
used to see if the items measured the same aspect. In all instances that more than 1 factor 
was recognised, the reason for this was the same: respondents evaluated not only the 
content of the material, but also the way the content/material was written. Cronbach’s alpha 
was determined to measure scale reliability. If Cronbach’s alpha was ≥0.60, the items were 
combined as 1 scale. If Cronbach’s alpha was <0.60, the least matching item was excluded 
and the remaining scales were combined. To evaluate the educational afternoon for arthritis 
nurses, differences between pre- and post-test at the group level were analyzed by t-tests. 
 
RESULTS 
Twenty-seven patients were included by a total of 16 reumatologists from 12 different centers. 
Additionally, 7 rheumatologists that did not see a suitable patient to include within the 5-month 
study period and thus evaluated only the information leaflet and booklet. This resulted in a  
total of 34 evaluations from rheumatologists. There were 13 male and 14 female patients 
included with a mean age of 57 years (SD:15, range 22-78). One patient was not able to read 
or write and did not evaluate the material. Ten arthritis nurses evaluated the material and 19 
patients consulted the arthritis nurse. 
 
Rheumatologists 
Rheumatologists were very positive about all aspects of the information leaflet and booklet 
(see Table 2). Rheumatologists felt that the information in the leaflet closely resembled the 
information given by themselves during the consultation (on a scale from -3 to +3: 2.0 
(SD:0.5)). Rheumatologists were also positive about the opportunity to provide patients with a 
specific information booklet: 2.0 (SD:1.0). Especially the use of the practical information 
during the explanation of COBRA therapy to the patient received high marks and was 
evaluated as very useful (2.3). Seventy-four percent of rheumatologists actually used the 
tables and figures from the booklet during the consult. Nearly all rheumatologists (94%) liked 
to have access to the material as provided in this study while prescribing COBRA therapy. 
While only 33% liked using the example consultation, 78% liked using the pre- printed 
prescriptions and 60% liked to have access to the background material. Eighty-eight percent 
of rheumatologists indicated that prescribing COBRA therapy went faster with the use of the 
provided material and 65% of rheumatologists expected to prescribe COBRA therapy to their 
patients more frequently with this material available to them. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Three pages of the COBRA therapy information booklet with helpful images and tables for rheumatologists, arthritis nurses and patients.  
For a more detailed overview, please visit the website at: www.cobratherapy.nl 
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Table 2   Evaluation of the patient information leaflet and booklet * 
 Scale 
(items) 
Question Mean (SD) 
-3 to 3 
Cronbach’s 
alpha  
(factors) 
Rheumatologists (n=34) 
 1(5) How does it feel to be able to give a leaflet containing a 
summary of the first consultation? 
2.3 (0.7) 0.80 (1) 
 2(3) How do you evaluate the information provided in the leaflet? 2.3 (0.6) 
  0.80 (1) † 
 3(4) How do you evaluate the appearance of the leaflet? 2.1 (0.9) 0.95 (1) 
 4(5) What is your opinion on the way the leaflet has been written? 1.6 (0.7) 
   0.63 (2) ‡ 
 5(1) Is the content of the leaflet similar to the first consultation of the 
rheumatologist? 
2.1 (0.5) Only 1 item 
 6(4) How does it feel to be able to give an information booklet 
containing detailed information on the prescribed treatment? 
2.0 (1.0) 0.70 (1) 
 7(6) How do you evaluate the interview in the booklet with a newly 
diagnosed RA patient? 
1.7 (0.9) 0.90 (1) 
 8(5) How do you evaluate the medical information provided in the 
booklet? 
2.2 (0.7) 0.83 (2) 
 9(5) How do you evaluate the practical information provided in the 
booklet? 
2.3 (0.5) 0.90 (1) 
 10(4) How do you evaluate the appearance of the booklet? 2.3 (0.6) 0.79 (1) 
Patients (n=26) 
 11(5) How does it feel to receive a leaflet containing a summary of the 
first consultation? 
2.5 (0.7) 0.90 (1) 
 12(4) How do you evaluate the information provided in the leaflet? 2.4 (0.6) 0.80 (1) 
 13(4) How do you evaluate the appearance of the leaflet? 2.5 (0.6) 0.90 (1) 
 14(5) What is your opinion on the way the leaflet has been written? 2.3 (0.8) 
   0.84 (2) ‡ 
 15(1) Is the content of the leaflet similar to the first consultation of they 
rheumatologist? 
2.6 (0.9) Only 1 item 
 16(5) How does it feel to receive an information booklet containing 
detailed information on the prescribed treatment? 
2.8 (0.5) 0.95 (1) 
 17(6) How do you evaluate the interview in the booklet with a newly 
diagnosed RA patient? 
2.2 (0.8) 0.94 (1) 
 18(5) How do you evaluate the medical information provided in the 
booklet? 
2.4 (0.9) 0.83 (1) 
 19(5) How do you evaluate the practical information provided in the 
booklet? 
2.5 (0.6) 0.82 (1) 
Arthritis nurses (n=10) 
 20(2) How do you evaluate the information provided in the leaflet? 2.6 (0.5) 1.00 (1) § 
 21(4) How do you evaluate the appearance of the leaflet? 2.4 (0.6) 0.90 (1) 
 22(5) What is your opinion on the way the leaflet has been written? 2.2 (0.7) 0.60 (2) 
 23(6) How do you evaluate the interview in the booklet with a newly 
diagnosed RA patient? 
2.2 (0.6) 0.90 (2) 
 24(4) How do you evaluate the medical information provided in the 
booklet? 
2.6 (0.5) 0.90 (1) 
 25(5) How do you evaluate the practical information provided in the 
booklet? 
2.3 (0.7) 0.90 (1) 
 26(5) How do you evaluate the appearance of the booklet? 2.4 (0.6) 0.90 (1) 
*  On a semantic differential scale from -3 most negative to +3 most positive 
†  One item excluded to improve scale reliability 
‡  The two factors reflect the content of the information in the leaflet and/or booklet vs the way the information has been 
  written. 
§  Two items are combined, so cronbach’s alpha is not representative 
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Patients 
Patients gave high marks to the consultation they had with their rheumatologist: 2.4 (SD:0.8) 
and were very pleased receiving an information leaflet 2.5 (SD:0.7) (See Table 2). Ninety-six 
percent of patients indicated to have kept the leaflet (1 patient did not). Patients indicated that 
the information in the leaflet showed close resemblance to the information given by the 
rheumatologist during the consult: 2.6 (SD:0.9). Sixty-nine percent of patients indicated that 
they used the leaflet to inform significant others: mostly family (90%) but also friends or 
acquaintances (16%), colleagues or employers (11%) and their general practitioner or 
pharmacist (11%). Another 16% planned to show it to significant others, but did not do so yet. 
Only 15% indicated that they did not plan to use the leaflet for this purpose. Patients were 
also pleased receiving an information booklet (2.8 (SD:0.5)). All patients reported to have kept 
the booklet and 89% planned to use it as a reference booklet. Seventy percent of patients 
used the booklet to remember the correct intake of their drugs and another 12% planned to 
use it for this purpose. The practical information in the booklet, like figures and tables were 
evaluated positively: 2.5 (SD:0.6) with 2.7 for usefulness and 2.6 for clarity. Furthermore, 
patients appreciated the effort of the arthritis nurse to call them every week during the first 
month of therapy: (2.3 (SD:1.1)). This was evaluated as being ‘of additional value’: 2.3. 
 
Arthritis nurses 
Eighty-six percent of the arthritis nurses used the tables and figures in the booklet during 
explanation of COBRA therapy to the patient. Ninety percent of arthritis nurses liked having 
background information on COBRA therapy as provided during the study. Forty percent 
thought that their colleagues in the Netherlands would not have sufficient knowledge on 
COBRA therapy and 80% felt it necessary to call the patient weekly one time during the first 
month of therapy. 
Eighty-seven arthritis nurses started the educational session on COBRA therapy and 
completed the pre-test questionnaire, 62 attended the session until the end and completed 
the post-test questionnaire. The pre-test results showed that 85% of arthritis nurses were 
familiar with COBRA therapy before announcement of the session and that 31% had 
experience with guiding patients on COBRA therapy. Forty-eight nurses (55%) had enough 
knowledge about COBRA therapy to be able to answer the attitude questions, although 56 
nurses (64%) answered the perceived capability-question. The pre-test results show that 
COBRA therapy was perceived as effective and safe, but somewhat complex (see Table 3).  
 
 
Table 3   Pre- and post test results of an educational intervention on attitudes towards 
COBRA therapy of arthritis nurses 
  
Attitude  ( range -3 to 3) 
    Pre-test (n=48) ‡   Post-test (n=62) 
  Mean (SD) Mean (SD) 
1 Ineffective / Effective  1.1 (0.8) *  1.8 (0.7) * † 
2 Unsafe / Safe  0.6 (0.9) *  1.1 (0.9) * † 
3 Complex / Simple -0.4 (1.1) * -0.7 (1.1) * 
4 Patient-unfriendly / Patient-friendly  0.3 (1.1)  0.5 (1.1) * 
5 Unsympathetic / Sympathetic  0.3 (0.9) *  0.7 (0.9) * † 
6 Unnecessary / Necessary  0.9 (0.9) *  1.2 (1.0) * 
7 Bad / Good  0.6 (1.1) *  0.8 (1.4) * 
8 Capability -0.3 (1.8) *  1.4 (1.1) * † 
7-point Likert-scale: value -3 most negative, value 3 most positive 
* Significantly different from the neutral point of 0 with p<0.05 
† Significantly different from the pre-test value with p<0.05 
‡ During pre-test, 48 arthritis nurses knew enough about COBRA therapy to answer question 1 to 7; 56 arthritis nurses 
 answered question 8 
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This is consistent with the initial opinion of rheumatologists’ found in phase 1 of this study14. 
Items on effectiveness and safety significantly improved after the educational session. 
Perceived capability to guide a patient with COBRA therapy improved significantly from a 
negative -0.3 to a positive 1.4 (p<0.001).  
 
DISCUSSION 
This article describes a pilot implementation study that was developed to facilitate prescription 
and use of COBRA therapy, a combination therapy of inexpensive, generic drugs, in early 
rheumatoid arthritis by the rheumatologist, the patient and the arthritis nurse. The 
implementation material was developed based on thorough qualitative research on perceived 
barriers and facilitators of rheumatologists and patients towards COBRA therapy. The 
rheumatologists, patients and arthritis nurses all highly appreciated the implementation 
material disposed to them. Furthermore, rheumatologists reported that in using this material, 
workload regarding prescribing COBRA therapy had significantly gone down. The far majority 
(88%) of rheumatologists indicated that prescribing COBRA therapy went faster with the use 
of the provided material. Moreover, 65% of the participating rheumatologists indicated that 
they would prescribe COBRA therapy to their patients more often, if they would have access 
to the material that was provided to them within the framework of the study. Arthritis nurses 
were also positive and no longer doubted whether their knowledge on COBRA therapy was 
sufficient to advise patients after the educational session. This study shows that the attitude 
and perceived capability of arthritis nurses towards the guidance of rheumatoid arthritis 
patients starting with COBRA therapy can be improved through a brief educational 
intervention. Furthermore, our goal of increasing prescription rate of COBRA therapy in daily 
practice by facilitating its use by rheumatologists, patients and arthritis nurses seems feasible 
with the current implementation material. 
It is a disadvantage of this study that there was no control group included in the design and 
that there was no pre- and post measurement design for evaluating the material. Although all 
questions to participants were aimed at comparing the situation wíth the material to the 
situation without the material, the consequence of our design choice is that we can not 
compare the impact of the implementation package with current daily practice, in which no 
material or support is available when rheumatologists want to prescribe COBRA therapy.  
Furthermore, our knowledge on barriers and facilitators from the arthritis nurses’ point of view 
were limited at the start of the implementation, for we initially focussed on doctors and 
patients. In knowing what we know now, it would have been better to involve arthritis nurses 
in a prior stage of the study. Nevertheless, their opinion on how to improve COBRA 
prescription in daily practice was not being overlooked. The ideas that were brought up by the 
arthritis nurses proved to be very useful in completing the implementation process. 
The educational session showed that knowledge of arthritis nurses on COBRA therapy was 
limited. Only 48 of the 87 nurses that started the session were able to answer the attitude-
questions about COBRA therapy, while all nurses that attended the session until the end 
(n=62) were able to answer the same questions again. Unfortunately, the questionnaires were 
anonymous, so we can not be sure if the same nurses that filled out the questionnaire before 
start of the session also completed it at the end. 
Important is that the rheumatologists that participated in this pilot study were rheumatologists 
with a positive attitude towards COBRA. The authors felt it necessary to address thís group of 
rheumatologists, because rheumatologists reluctant to use the therapy would probably not 
cooperate in the short duration of this trial. It is possible that rheumatologists with a very 
negative attitude towards COBRA therapy would still not use it in practice, even if the material 
tested in this study would be available to them. In this case, workload or fear for the patients’ 
perception was not the real barrier for them, which would have made this group unsuitable to 
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test the implementation material. Grol et al have done extensive research in the field of 
implementation and showed that the compliance of Dutch general practitioners to 
recommended guidelines was lower when recommendations were incompatible with 
clinicians’ norms and values and if they were disruptive of routine practice17. A well known 
theoretical model that explains the uptake of knowledge is Rogers’ diffusion of innovations’ 
model; besides characteristics of the innovation itself (such as its relative advantage, 
compatibility, complexity, flexibility, and costs or risks attributed to the innovation), the 
diffusion process may be further influenced by the individual characteristics of the five adopter 
categories: the so called innovators are followed by the early adopters; next comes the larger 
group of early majority, then late majority, followed by the so called ‘laggers’, that will never be 
persuaded to adopt a new strategy18. 
Lessons learned from this pilot study are that a larger, more controlled study on the 
implementation of a treatment strategy should include a more divers group of rheumatologists 
(from all stages of the diffusion of innovations model), allow more time for inclusion of patients 
and specify the facilitators and barriers from the nurses’ point of view in an earlier stage. 
Our implementation strategy might be applicable to other strategies with low uptake. 
Substitution of branded drugs for generic drugs is a ‘hot’ topic in which there are large 
economic interests of health care systems19. Health insurance companies might be interested 
to cooperate in national implementation. 
In summary, rheumatologists, patients and arthritis nurses all highly appreciated the disposed 
materials and indicated that the use of these would stimulate prescription of the COBRA-
therapy, which is a ‘high dosage generic drug therapy’, in the future. Thus, in the situation of 
an effective therapy that is unpopular in the eyes of the physician, or is not promoted by 
pharmaceutical companies like generic drugs, this article suggests that an implementation 
approach of identifying and addressing barriers with tailored materials can overcome those 
barriers and increase uptake of the therapy. 
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NOTE 
For more information on COBRA therapy a website has been developed, were patients, 
rheumatologists and arthritis nurses can find information on COBRA therapy, as well as all the 
information material (booklet, leaflet, pre-printed prescriptions, background information) used 
in this study. Visit the website at: www.cobratherapy.nl 
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ABSTRACT 
 
 
OBJECTIVE 
To investigate the feasibility of a new aggressive treatment strategy in early rheumatoid 
arthritis (RA) combined with monitoring of disease activity (measured by the disease activity 
scale with 28-joint count, DAS28) and cartilage degradation (measured by urinary excretion of 
C-terminal cross linking of type-II collagen (CTX-II).  
 
METHODS 
In a randomized double-blind pilot-trial, 21 patients with active early RA (mean DAS28 5,3; 
mean disease duration 3 months) were initially treated with an intensified COBRA strategy 
comprising sulfasalazine, hydroxychloroquine, methotrexate and high dose step-down 
prednisolone. Patients were randomized into two groups (DAS-group and CTX-group), 
receiving treatment intensification according to either achieved levels of DAS28 or urine CTX-
II. When the cut-off level for response rate (DAS28<3.2 or CTX-II<150) was not reached at 8 
weeks, MTX was intensified; when it was not reached at 21 weeks, infliximab was offered to 
patients on high-dose MTX, and MTX was intensified in the remainder. The treatment advice 
(intensification: yes or no) had to be available for the physician within 1 week. 
 
RESULTS 
Overall, almost all patients (90%) achieved a DAS28<2.6 after 40 weeks of treatment, but 
only 50% reduced their CTX-II excretion below the cut-off point. The two monitoring groups 
showed no significant difference in remission according to DAS-score or CTX-II excretion, 
despite a trend towards more intensive treatment in the CTX-II group. Treatment 
intensification was feasible according to protocol. 
 
CONCLUSION 
In this pilot study almost all patients achieved DAS28 remission on this new intensified 
COBRA strategy, whereas the CTX-II target proved harder to attain. Monitoring intensive 
treatment in early RA through measurement of CTX-II is feasible in the context of a clinical 
trial.  
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that often leads to severe joint 
damage1. Treatment of RA is ultimately aimed at remission. Current more realistic targets of 
treatment comprise suppression of disease activity, improvement of functional ability and 
slowing-down of radiographic joint damage2-4.  
In the last decade treatment for RA has improved, especially through the introduction of TNF 
blocking agents. These drugs provide high response and remission rates, especially in 
combination with traditional drugs such as methotrexate (MTX)5,6. Combinations of traditional 
drugs also achieve good results7-10, including initial combination therapy with tapered high-
dose prednisolone, methotrexate and sulfasalazine (COBRA therapy)7. COBRA recently 
proved equivalent to the combination of high-dose MTX and infliximab in inducing rapid 
remission, and better than monotherapy or step-up combination therapy11. Increasingly, 
strategies aim at tight control of disease activity with adjustments of treatment in case of 
insufficient response12,13. To date, the highest one-year remission rate reported in early RA is 
68%9. 
It is unclear whether measurement of disease activity suffices as indicator of damage arrest in 
RA. Damage progression may be partially independent of disease activity14: studies suggest 
non-responders can show slowing of progression on biologic therapy15 but also that patients 
in clinical remission can still show progression16.  
In this setting, a new predictor of radiographic damage, i.e. urinary excretion of C-terminal 
cross linking of type-II collagen (CTX-II) may have high potential. CTX-II, a biochemical 
marker of cartilage degradation, predicted 5-year radiologic progression better than 
rheumatoid factor, baseline damage and disease activity in follow up data of the COBRA trial 
cohort17. A treatment start with COBRA combination therapy suppressed CTX-II significantly 
better than a treatment start with sulfasalazine (SSZ)18. In addition, a level of CTX-II could be 
identified (150 ng/mmol creatinine excretion, measured in the urine) below which almost no 
further radiologic progression occurred and which is similar to levels of healthy controls. 
Recently, longitudinal analysis showed that inflammation immediately causes cartilage 
degradation19. Thus, we hypothesized CTX-II might be more useful as a monitor for treatment 
intensification than disease activity measured by the disease activity score (DAS). 
The aim of this pilot study was to compare the feasibility of tight control based on 
measurement of disease activity or cartilage degradation and to test the acceptability of 
intensive treatment.  
 
PATIENTS AND METHODS 
Patients 
A total of 21 patients were recruited between July 2004 and November 2005 in 2 centers: the 
Jan van Breemen Institute and the VU University Medical Center, Amsterdam, The 
Netherlands. A third center was unable to include patients. Inclusion criteria were: a diagnosis 
of rheumatoid arthritis 36 months or less prior to inclusion (according to American college of 
Rheumatology (ACR) criteria20); and active disease defined by a 28-joint disease activity 
score (DAS28)>3.221. Patients were excluded from participation if they had received previous 
treatment of RA with more than two DMARDs (including systemic glucocorticoids) and if 
patients had increased risk of harm due to contraindications to the study drugs. Patients who 
had used any investigational product within 30 days prior to enrollment were excluded, as 
were patients below 18 years of age. The study protocol was approved by research and 
medical ethical committees in both centers. The patients were informed in detail about the 
potential side effects of all drugs; all patients gave written informed consent. 
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Intervention 
Patients were randomized into two groups, further to be referred to as the DAS-group and the 
CTX-group. In the first 8 weeks, both groups were treated identically, i.e. with a modified 
COBRA scheme comprising hydroxychloroquine (HCQ, 400 mg/d), sulfasalazine (2 g/d), 
methotrexate (10 mg/w) and tapered high dose prednisolone (60 mg (wk 1); 40 mg (wk 2); 30 
mg (wk 3); 20 mg (wk 4); 15 mg (wk 5); 10 mg (wk 6); 7.5 mg (thereafter)). All patients 
received additional calcium 500 mg/Vit D3 400 IU daily and 5 mg folic acid weekly. Patients 
with a low bone mineral density (BMD, T≤-1 at baseline) received a bisphosphonate 
(alendronate). The lower panel of Figure 1 illustrates the study treatment schedule. 
Treatment was intensified in two steps when the predefined targets were not met. In the group 
monitored by disease activity the target was DAS28 ≤3.2; in the group monitored by cartilage 
degradation the target was CTX-II ≤150 ng/mmol creatinine. The DAS28 target was chosen to 
correspond with Dutch standards of reimbursement of anti-TNF therapy and is defined by the 
European League Against Rheumatism (EULAR) as low disease activity22. The CTX-II target 
was chosen based on follow up research of the COBRA trial where patients with a CTX-II 
excretion below 150 ng/mmol creatinine showed almost complete arrest of radiologic 
progression18,19. When the target (DAS28 or CTX-II, respectively) was not met at 8 weeks, 
MTX was intensified from 10 to 25 mg/wk in 2 weeks; if still not met at 21 weeks infliximab 
was offered. In patients initially meeting the target at 8 weeks, but not at 21 weeks MTX was 
intensified. The protocol ended after 40 weeks; the treating physician was then at liberty to 
start alternative therapies. 
 
Treatment allocation 
Patients were assigned a unique study number, linked to random allocation (generated by 
computer) to one of the two monitoring groups with stratification by center. Patients, the 
treating physicians, and assessors were blinded for allocation to the monitoring groups. 
Treatment decisions (intensification yes/no) based on disease activity and CTX-II results were 
communicated to the treating physician by fax. Treatment advice had to be available for the 
treating physician within 1 week. 
 
Outcome measurements 
Disease activity, functional ability and remission 
Disease activity was measured by one trained research nurse in each center (at baseline and 
weeks 8, 21, 32 and 40) who was not involved in any treatment decision. Disease activity was 
measured by the DAS2821. At the same time points, urine CTX-II was measured by ELISA 
(Cartilaps®, Nordic Biosciences, Herlev, Denmark) in a specialized central laboratory 
(Synarc, Lyon, France)23. Intra and inter assay coefficients are lower than 6 and 11%, 
respectively.  
Functional ability (Dutch modified version of the health assessment questionnaire (HAQ)) with 
scores ranging from 0 for ‘best’ and 3 for ‘worst’24 and other core patient-reported endpoints 
were measured at baseline and 4-weekly thereafter. Success was defined by DAS28 
remission (≤2.6) for the DAS-group and urine CTX-II ≤150 nmol/mmol creatinine excretion in 
the CTX group.  
Radiologic progression and bone mineral density 
Radiographs of hands and feet were obtained at baseline, at 21 weeks and at 40 weeks. The 
radiographs of 17 patients (baseline and at least one during follow up) were available for 
assessment, 9 in the DAS-group and 8 in the CTX-group.  
Films were scored for damage independently and in chronological order by two trained 
observers blinded to group allocation, according to the Sharp/van der Heijde method25,26. 
Results are the mean of the two observers’ scores. Agreement was high with an inter-
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correlation-coefficient for total scores of .94, of erosion score of .96 and of narrowing score of 
.94. In one patient a consensus score had to be reached after initial discrepancy. This patient 
had extensive hand osteoarthritis and observers initially disagreed on scoring rules.  
Dual-energy x-ray absorptiometry (DEXA) was performed: changes in BMD in the 
anteroposterior lumbar spine at L2-L4 and the total hip at baseline and at 40 weeks were 
measured. 
Feasibility 
Feasibility was studied for: 1) procedures (eligibility, randomization, monitoring of side effects, 
outcome measurement documentation), 2) acceptability of the protocol to patients and study 
participants (with special regards to the proportion of eligible patients that would be willing to 
enter a follow up trial, and be randomized to receive, in addition to their current treatment 
infliximab or placebo, i.e. after ‘failure’ but still low disease activity by current standards) and 
3) treatment intensification according to protocol (including logistics, timeliness and 
interpretability). 
Toxicity and monitoring 
Adverse events were documented. Laboratory monitoring comprised routine blood 
hematology and biochemistry as well as urinalysis for glucose and albumin. In addition, 
rheumatoid factor (U/ml) and anti-cyclic citrullinated peptide (U/ml) were assessed at every 
control visit.  
 
Statistical analyses 
Differences between groups were tested by t-tests or non-parametric tests where appropriate. 
Differences between categorical variables were tested by chi-square test.  
As bisphosphonates may interfere with CTX measurements27, extra attention was paid to 
users vs non-users. Due to the skewed distribution of the radiologic data, median values are 
reported in addition to means and standard deviations (SD). 
 
RESULTS 
Twenty-one patients were included in the trial. All patients had early and active disease, with 
a mean disease duration between diagnosis and inclusion of 3 months. One patient was 
included 19 months after diagnosis, while all others were diagnosed less then 8 months 
before inclusion. The mean DAS28 (SD) was 5.3 (0.8). The groups were well matched at 
baseline (Table 1).  
 
Clinical outcomes 
Overall, 90% of patients (19 out of 21) achieved a DAS28 remission after 40 weeks of 
intensive treatment (95% confidence interval (CI), 70-99%; Figure 1). One patient dropped out 
at 28 weeks to work abroad; at 21 weeks, DAS28 was 1.12 and CTX-II was 246. These 
values were carried forward to weeks 40. 
Response was brisk with 57% in remission after 8 weeks, and 76% after 21 weeks (Figure 1 
and 2). The mean (SD) DAS28 after 40 weeks was 1.6 (1.1) and the duration of remission for 
the 19 patients was mean (SD) 28 (11) weeks.  ACR20, 50 and 70 improvement rates (95% 
CI) at week 40 were 100% (84%-100%), 95% (76%-100%) and 71% (48%-89%) respectively 
(Figure 2). Mean (SD) ACR response, expressed in the new ACR hybrid measure25 was 79.0 
(17.6). There were no differences in response between the monitoring groups. Changes in 
DAS28 and CTX-II over the trial period were very similar in both monitoring groups (Figure 1 
and 3). Mean (SD) HAQ score after 40 weeks of treatment was 0.36 (0.62) for the DAS group 
and 0.10 (0.17) for the CTX group, and changes in this and other endpoints were also very 
similar (data not shown). CTX-II decreased strongly and similarly in both groups (Figure 3). At 
week 40, 48% had CTX-II levels below 150 ng/mmol creatinine. 
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Seven patients required bisphosphonates at the start of the study; one patient was already 
using bisphosphonates before inclusion. In these 8 patients CTX-II levels in urine decreased 
more, resulting in more CTX-remissions at week 40: 75% for bisphosphonate users versus 
33% for non-users (p=0.17). 
 
 
* Mean (SD) or count (%) unless stated otherwise 
† Significantly Scores decrease on improvement 
‡ During Missing data for one patient 
§ Missing data for two patients 
 
 
Monitoring decisions 
As shown, the CTX-II target tended to be more challenging than the DAS28 target. At 8 
weeks, MTX intensification rates were 36% (4 out of 11) in the group monitored by DAS28 
versus 60% (6 out of 10) in the group monitored by CTX-II. At 21 weeks, 27% (3 out of 11) 
versus 50% (5 out of 10) were offered infliximab, and 27% versus 33% accepted. Additionally, 
0 versus 10% (1 out of 10) received MTX intensification at this time (See Table 2). None of 
these differences in treatment intensity were statistically significant. At 8 weeks, monitoring by 
DAS28 or CTX-II would have yielded the same treatment decision in 10 out of 21 decisions; 
the disagreement in 11 decisions was 9 times due to high CTX-II/low DAS28 and 2 times due 
to high DAS28/low CTX-II (1 bisphosphonate user). At 21 weeks, 10 out of 21 decisions 
would have been the same; disagreement for 11 decisions was 8 times due to high CTX-II/low 
DAS28 and 3 times due to high DAS28/low CTX-II (2 bisphosphonate users). Given the 
protocol design, 6 patients in the CTX-group received intensified treatment at 8 and/or 21 
weeks despite being in DAS remission. In contrast, one of the two ‘remission failures’ at week 
40 reached the CTX-II target at week 8 and thus did not receive MTX intensification, despite a 
DAS28 above 3.2 (Figure 1). At week 21, the treating physician violated the protocol to 
increase the MTX dose, to which the patient did not respond. The other ‘remission failure’ at  
 
Table 1   Baseline characteristics of study participants* 
Characteristic  Monitoring group 
 DAS group (n=11) CTX group (n=10) 
Age (years)   52 (14)  50 (13) 
Female  8 (73%)  6 (60%) 
Duration of symptoms before diagnosis 
(months) 
 9 (11)  13 (7) 
Disease duration (from diagnosis up to 
inclusion, months) 
 2 (2)  4 (6) 
Previous DMARD therapy  4 (36%)  3 (30%) 
DAS28†  5.37 (0.98)  5.19 (0.62) 
Tender joint count (range, 0-28)  8 (5)  7 (4) 
Swollen joint count (0-28)  10 (6)  7 (3) 
Pain score (0-100)†  56 (29)  56 (17) 
Patient global assessment (0-100)†  58 (25)  55 (15) 
Physician global assessment (0-100)†  65 (18)  58 (18) 
HAQ (0-3)†  0.93 (0.74)  1.27 (0.61) 
CTX-II (ng/mmol creatinine)  546 (324)  450 (300) 
ESR (mm/h)  36 (29)  30 (21) 
RF positive   8 (73%)  7 (78%)‡ 
aCCP positive  8 (73%)  8 (89%)‡ 
Erosions on hand/foot radiographs  5 (56%)§  6 (75%)§ 
Total Sharp/vd Heijde score, mean (SD) median  6.8 (11.8) 3.0§  8.5 (11.2) 4.3§ 
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Figure 1  Disease activity (DAS28) during 40 weeks of intensive treatment in the two monitoring groups. 
Remission is defined as DAS28<2.6 (top panel light grey shading). Lower panel: all patients received the 
original COBRA schedule (black), intensified by the addition of hydroxychloroquine, methotrexate 10 mg 
instead of 7.5 mg and continuation of low-dose prednisolone instead of tapering after 28 weeks (dark 
grey). Decisions to intensify methotrexate and to start infliximab infusions (light grey) were made when 
DAS28 (DAS-group) or CTX-II (CTX-group) target levels had not been met. 
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week 40 did receive both MTX and infliximab and can be considered a true failure, although 
she did reach an ACR70 response, and the final DAS28 of 3.55 can be considered moderate 
disease activity by current standards. 
 
Radiologic progression & bone mineral density 
Baseline damage was comparable in both groups (Table 1). At 40 weeks median increase 
was 0.5 (mean; SD: 2.9; 5.5) in the DAS-group and 1.2 (2.2; 2.8) in the CTX-group. There 
were no significant differences in progression between the monitoring groups, 
bisphosphonate users/non users or patients achieving CTX-II remission yes/no. Two patients, 
1 in the DAS-group and 1 in the CTX-group, had a high baseline score (37 and 34 
respectively). These two patients and one additional patient from the DAS-group also showed 
a high progression rate. This made the results in this small group of patients complicated to 
interpret.  
BMD measurements at baseline and at 40 weeks were available for 18 patients, 10 in the 
DAS-group and 8 in the CTX-group. After 40 weeks, BMD at the lumbar spine (L2-L4) 
increased by 0.2% (SD 3.6), and BMD in the total hip decreased by -0.4% (SD 2.7). 
 
 
 
 
Figure 2   Percentages of ACR20, 50, 70 and DAS28 responses during 40 weeks  of  
intensive treatment for all patients.  
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Figure 3  Mean (95% confidence interval) urine CTX-II levels during 40 weeks of intensive treatment in 
both monitoring groups (light lines, DAS-group; dark lines, CTX-group). The dotted reference line at 150 
represents the CTX-II target. 
 
 
Safety 
Eight adverse events were registered, for 8 different patients, all rated low to moderately 
severe. Of the four events in the DAS-group, 2 were likely the result of the study medication, 
which was temporarily lowered in one case (case 3, see below), and permanently stopped in 
the other (case 2). In the CTX-group, one case of exacerbation occurred; the treatment advice 
of no MTX intensification was ignored, and MTX was intensified (case 5). Two other events 
were possibly caused by the study medication, and were followed up by temporary stop of 
one or two drugs (cases 1 and 4). In more detail: (1) fatigue since start of therapy; (2) malaise 
and mood disorder after reintroduction of SSZ and HCQ; (3) headache since start; (4) 
bronchitis; (5) persistently active disease after 21 weeks; (6) nausea, diarrhea, potential for 
dehydration; (7) two falls without further injury; (8) dyspnea. 
 
Feasibility 
Treatment intensification according to DAS28 in the DAS-group and urine CTX-II in the CTX-
group per protocol proved feasible. Eligibility criteria, randomization to one of monitoring 
strategies, clinical assessments of DAS28 and measurements of urine CTX-II gave no major 
problems; however, the logistics of measurement, processing of urine CTX-II and briefing the 
final result to the treating physician within one week, proved fairly complex and time-
consuming and needed careful planning. At 8 weeks, as well as at 21 weeks, 5 out of 21 
treatment recommendations came too late for the treating physician (mean 3 days late). In 
addition, the complexity of the study protocol, addressing multiple research questions, 
demanded full attention of all participants. Monitoring of side effects and documentation of 
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outcome measurement were as feasible as in other clinical trials. After 21 weeks of intensive 
therapy in one of the two monitoring arms, 65% of all patients expressed willingness to enter 
the hypothetical follow up trial comprising treatment with infliximab or placebo. 
 
 
Table 2   Number of patients reaching the DAS28 or CTX-II target (yes/no)            
at every intensification step  
    Yes        n=2 
   Yes              n=3 † No     n=1 
  Yes           n=4 No: MTX       n=1 Yes        n=1 
CTX-group n=10    
  No: MTX     n=6 Yes             n=1 Yes        n=1 
   No: IFX         n=5 ‡ No n=4 * 
        
Weeks 0 8  21  40  
        
  Yes           n=7 Yes             n=7 Yes        n=7 
DAS-group n=11    
  No: MTX    n=4 Yes        n=1 Yes        n=1 
   No: IFX     n=3 Yes     n=2 
    No     n=1 
* 1 patient missing; CTX-II at 21 weeks >150 
† 1 patient received MTX intensification despite reaching the CTX-II target because of high clinical disease activity 
‡ 2 patients refused IFX because of low disease activity 
Yes: CTX-II≤150ng/mmol creatinine or DAS28≤3.2; No: CTX-II>150ng/mmol creatinine or DAS28>3.2 
 
 
DISCUSSION 
This small pilot study documents a uniquely high DAS28 remission rate of 90% in patients 
with active early RA achieved through tight control and aggressive combination therapy. 
Remission rate was rapid and sustained. Such a high remission rate has not been reported 
before and its lower confidence limit (70%) still exceeds the best results published so far. 
Likewise, the ACR improvement rates are also well above response rates noted in the 
literature.  In contrast, a CTX-II remission, here defined as urine CTX-II levels ≤150 ng/mmol 
creatinine, was less easily attained, and was independent of more aggressive treatment 
intensification in the CTX-group.  
Despite the low number of patients in this study, a DAS28 remission percentage of 90% is 
extraordinary. Reported remission rates of 25 to 50, mostly in trials of early RA patients, are 
generally associated with a good response to therapy. Previous research on COBRA 
combination therapy, comprising a combination of sulfasalazine, methotrexate and 
prednisolone, resulted in 28% remission after 28 weeks of intensive treatment7. The more 
recently published BeSt study, using a DAS controlled strategy and allowing for dosage 
increments of MTX, resulted in remission rates of 29 to 36% (DAS44<1.6) after one year11. 
Trials evaluating the efficacy of MTX in combination with a biological show similar results; the 
TEMPO trial, comparing the combination of MTX with etanercept to both drugs alone, showed 
a 38% remission rate after one year29. The PREMIER study, comparing adalimumab plus 
MTX versus either monotherapy, showed similar 1-year remission rates for the combination 
therapy group of 43%, with half the remission rates in both monotherapy groups5. In tight 
control strategies that adjust treatment in case of insufficient response8-11-13, the maximum 
rate was 51%, with exception of the FIN-RACo trial reporting 68%9. Caution must be used in 
these comparisons, as baseline disease severity of the patients differs between trials. 
However, the patients included in our study had several markers of a poor prognosis: high 
disease activity, and high rates of seropositivity and baseline joint damage. 
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Several explanations may be offered for the high remission rates found in our study. Firstly, 
the treatment schedule was more intensive than either COBRA or BeSt, with HCQ added to 
the original COBRA treatment schedule and MTX starting at 10 mg/w and intensification 
modelled after the BeSt trial. With the fast introduction of infliximab (after at least 21 weeks 
‘failure’), patients were treated very intensively. Secondly, the first intensification step took 
place, if necessary, after 8 weeks of treatment, as opposed to 3 months of therapy in the BeSt 
study. Finally, treatment itself was not blinded; doctors, research nurses and patients were 
blinded for the allocation to a monitoring strategy, but they all knew that the treatment 
consisted of a very effective therapy. This might have introduced a bias, towards more 
remissions. 
Only about half of patients reached a CTX-II remission. This relative low CTX-II response 
might be explained by a too strict definition. The cut-off point of 150 ng/mmol was chosen 
based on receiver operating characteristics (ROC) curve analysis on follow up data of the 
COBRA trial cohort showing almost no further radiologic progression below this level18. The 
level is similar to levels of CTX-II excretion in urine found in healthy controls, but may be too 
low to define remission in RA patients. Another explanation may be the uncoupling of damage 
progression and disease activity. Although not uncontested30 this has been suggested to 
occur in patients without clinical benefit that still show slowing of progression14,15 and 
conversely in patients in clinical remission that still show progression16. In this explanation, 
CTX-II levels above the cut-off despite aggressive treatment would reflect ongoing damage 
progression despite mostly adequate disease activity control. Unfortunately, this study was 
not powered to support this hypothesis with the radiologic data. A large therapeutic trial might 
clarify the ongoing debate around the hypothesis that clinical disease activity and radiologic 
damage are mediated by different disease processes as summarized by Kirwan31.  
This study suggests that the use of bisphosphonates might result in greater decrease of CTX-
II in urine during intensive RA treatment. It is important to monitor bisphosphonate-use when 
studying this process in larger groups of patients, so that the possible confounding effect can 
be taken into account during analysis. 
A limitation shared with all current RA trials is the definition of remission. The original ACR 
remission criteria3 lack feasibility and may be replaced by the full joint count DAS criteria32. 
However, the widely used DAS28 criteria33 are less strict and allow inclusion of patients in a 
minimal disease activity state34,35. Thus a group of patients in DAS28 ‘remission’ as currently 
defined probably includes patients with some residual level of disease activity. 
 
In summary, this study has shown that early aggressive treatment of patients with active RA 
in which treatment intensification is guided by measurements of CTX-II or DAS28, results in 
remarkably high DAS28 remission rates, while CTX-II remission, defined as CTX-II ≤150 
ng/mmol creatinine, is harder to attain. A larger, powered trial using this treatment and 
monitoring strategy is feasible and might clarify the use of CTX-II as guidance for treatment 
intensification. 
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